<<

USOO8480637B2

(12) United States Patent (10) Patent No.: US 8,480,637 B2 Ferrari et al. (45) Date of Patent: Jul. 9, 2013

(54) NANOCHANNELED DEVICE AND RELATED USPC ...... 604/264; 907/700, 902,904, 906 METHODS See application file for complete search history. (75) Inventors: Mauro Ferrari, Houston, TX (US); (56) References Cited Xuewu Liu, Sugar Land, TX (US); Alessandro Grattoni, Houston, TX U.S. PATENT DOCUMENTS (US); Daniel Fine, Austin, TX (US); 5,651,900 A 7/1997 Keller et al...... 216,56 Randy Goodall, Austin, TX (US); 5,728,396 A 3/1998 Peery et al...... 424/422 Sharath Hosali, Austin, TX (US); Ryan 379.83- w A SE us et al...... 210,490 Medema, Pflugerville, TX (US); Lee 5,893,974 A 4, 1999 Keller et al. ... 510,483 Hudson, Elgin, TX (US) 5,938,923 A 8/1999 Tu et al...... 210,490 5,948.255. A * 9/1999 Keller et al. ... 210,321.84 (73) Assignees: The Board of Regents of the University 5,985,164 A 1 1/1999 Chu et al...... 516,41 of Texas System, Austin, TX (US); The 5,985,328 A 11/1999 Chu et al...... 424/489 Ohio State University Research (Continued) Foundation, Columbus, OH (US) FOREIGN PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this W W 38E. d38 past list: listed under 35 W. Wooyo 12/2009 M YW- y to 12 dayaWS. OTHER PUBLICATIONS (21) Appl. No.: 12/618,233 “Under the Counter: The Diversion and Abuse of Controlled Pre 1-1. scription in the US.” The National Center on Addiction and (22) Filed: Nov. 13, 2009 (CASA) at Columbia University, New York, NY. (65) Prior Publication Data CASA, Jul. 2005. US 2010/0152699 A1 Jun. 17, 2010 (Continued) Primary Examiner — Manuel Mendez Related U.S. Application Data Assistant Examiner — Gerald Landry, II (60) Provisional application No. 61/114,687, filed on Nov. (74) Attorney, Agent, or Firm — Parker Highlander PLLC 14, 2008, provisional application No. 61/168,844, (57) ABSTRACT filed on Apr. 13, 2009. A nanochannel delivery device and method of manufacturing (51) Int. Cl and use. The nanochannel delivery device comprises an inlet, A. iM 25/00 (2006.01) an outlet, and a nanochannel. The nanochannel may be ori (52) U.S. Cl ented parallel to the primary plane of the nanochannel deliv USPG 604/264: 604/43 ery device. The inlet and outlet may be in direct fluid com (58) Field of- -Classification ------Search------s U1Ca1OW1icati ith th aOClaeh 1. CPC ...... B82Y 4O/OO 15 Claims, 35 Drawing Sheets

US 8,480,637 B2 Page 2

U.S. PATENT DOCUMENTS Nath et al., “ : relative bioavail 6,044,981 4, 2000 Chu et al...... 210,490 ability of Sublingual tablet and liquid formulations.” J. Clin. 7,025,871 4, 2006 Broadley et al. 205,793 Pharmacol. 39:619-623, 1999. 7,135,144 11, 2006 Christel et al...... 422,527 Report Stakeholder Workshop on a National Buprenorphine Program 7,326,561 2, 2008 Goodman et al. . 435/286.5 Health Canada Nov. 18, 2004. 2004.0011647 1, 2004 Broadley et al...... 204,435 Samhsa, "Overview of Findings from the 2002 National Survey on 2004/O116905 6, 2004 Pedersen et al. 604/890.1 Use and Health.” Rockville, MD, DHHS publication, SMA 2004/0260418 12, 2004 Staats ...... 7OO/97 O3-3774. 2006, O180469 8, 2006 Han et al...... 204f601 Samhsa, “Results from the 2003 National Survey on Drug Use and 2007/0066138 3, 2007 Ferrari et al. ... 439,607.01 Health: National Findings.” Rockeville, MD, DHHS publication, 2007/OO77273 4, 2007 Martin et al. ... 424/423 S.MA 04-3964. 2008.OO73506 3, 2008 Lazar ...... 250/288 Samhsa, “The DAWN Report: Oxycodaone, , and 2009/0214392 8, 2009 Kameoka et al...... 422/102 polydrug use.” 2002. Jul. 2004 http://oas. Samhsa.gov/2k4/ ?oxycodone.cfm. OTHER PUBLICATIONS Extended European Search Report issued in European Application No. 09826831, mailed Jul. 12, 2012. “The Economic Costs of Drug Abuse in the United States,” www whitehousedrugpolicy.gov, Sep. 2001. * cited by examiner U.S. Patent Jul. 9, 2013 Sheet 1 of 35 US 8,480,637 B2

U.S. Patent Jul. 9, 2013 Sheet 3 Of 35 US 8,480,637 B2

FIG. 20

FIG. 2D

U.S. Patent Jul. 9, 2013 Sheet 5 Of 35 US 8,480,637 B2

Ø

FIG. 3B

// .//…***~~~~).... U.S. Patent Jul. 9, 2013 Sheet 6 of 35 US 8,480,637 B2

FIG. 3D U.S. Patent Jul. 9, 2013 Sheet 7 Of 35 US 8,480,637 B2

FIG. 3E

S

/// (/.

FIG. 3F U.S. Patent Jul. 9, 2013 Sheet 8 Of 35 US 8,480,637 B2

FIG. 3G U.S. Patent Jul. 9, 2013 Sheet 9 Of 35 US 8,480,637 B2

U.S. Patent Jul. 9, 2013 Sheet 10 Of 35 US 8,480,637 B2

N N SN

• ---x^^ 3------/-)-2-// 2 ii if 11161, 1% ^ % 1, -----: 1444 u-220

2.3 3. 3------a. --- 2. 2. - If I i 3333222222222222222232 -: --. 1. 2. 33.a--- - 3 3.^x. 2. 262. % 32 23,22. 3 2--- 32. 23 s%3. -3 3 2 3 32. 3.33 2. 22- 2. 32 3 2. - × - × 32 23 2 3.3 3 333 3 2. 332. 3 2. 222222222222223. 2 33.33 a.3. 2

22. ------M 32222222 3-

---. ----- . -

2 3 W. 23 3 36. 2 23-dz2.

2 T 3.3223.3 22 2. 3. % 2. 3 --> 33X a. - 3.>2 3a. 32.--- 222 %32.- - ^^^- 3^ 2,it initial33 3 3 - 250 23233 22 33 22 3 3 2 2. 3 322. × 33223222222222 2. --> 2. 3 3, 33. - 2 33.3 23

U.S. Patent Jul. 9, 2013 Sheet 13 Of 35 US 8,480,637 B2

FIG. 5H U.S. Patent Jul. 9, 2013 Sheet 14 of 35 US 8,480,637 B2

U.S. Patent Jul. 9, 2013 Sheet 15 Of 35 US 8,480,637 B2

430

3 - 420 3 3 2 3 3 & s3 %3 2. 33 TITIATIII, III, III ITT.III. T.I.T.3 - 450 Z 32. 3 3

3 410

3 - - - - - 2 3 2 323 32. 3

FIG. 8A U.S. Patent Jul. 9, 2013 Sheet 16 of 35 US 8,480,637 B2

SS é2. & SSSSSSSSSSSSSS SSS3

3Se

22. : s illili 3- -. - - 2. ^^^X. XX ^ --- 23 3.2 3- ---XX.22.2,2. 3.2. 2 3-2. d 32 23 3 3.------2. ------> 2.3 3s 3in x. 2. 2. xxx^ 3. ^s 22 2. 2 2. &-- a MX^ 2 2.3 3 2. 2. %s 32, 3 23 2 3 3 22 % 3 3.3 ^.3. &2. 2,222. 3 2 3 33. 33 3. 2. 2.32 3/410 3 ------2. W. 2.2.3 2,2. 33 -----> 3 X 3% 2 3 22:32:3- - 3s322 2. a. × 22. 32. 3 2 > 3 --- 2 % % 3 3% 3 3 - 2.3 32. FIG. 8B

SNS

SxYSSYS SSSSSSS NN

M - X ^^^^ 223 2.%3 3 M 3 %23. 2 :::::::

------> Ll l ill Hill ill &: Lil --- x. ^ -- ^. t 2 2.. 32 333 3 2 .. 22. ^^^X^^. -- 232 ..a - ---- 8. ^^^ ^ M 22. 2. . 2. 333.22.22%. 3. 32, 3 - ---. - 3-. - M - 6 - M - 3 %^. 3 2. 22 32 3 3 233 3 3. % 3 2 32 32 3 -. 23 3%

32222222223 23 U.S. Patent Jul. 9, 2013 Sheet 17 Of 35 US 8,480,637 B2

41 1-1 441

441 421 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS SSSSSS NXXX SSS SS Sy y SS SS NY. S. SSS SS SS SS y^N SS NX SS SSSSSS Ny S SS SNSS - N- - SS Š SSX N NN N N N 411 N NSy NS. S SSSSSSSSSN S S SS S S NSSSSSSSSSSSSSSSSSSSSS N N NN N N r SSN SSN SSSSSN SS SSSN S&S NSSSSSSSS NSNSX-N SS S\ N N& S. SSSSSN N SX N S S N N N ySN N SSN NNS w N SS. NNN. ŠSSS N N SSSSSSSSSSSSSSSSS y - s s S. S. S. N NS.

S N N S SS S NS S S SS

N S N SN

NNSS SSNS N&YYXX^XXX S. SSSS N

NxYxxx N -

TTT T S ------

3 3 %3^

& 3 8 j i ; É.i.i. i. lili 323-y 3. & 450 2 232. 333 %32 2% ---. a------> -

s 3. % 3 % 2. M 2

& ^^ M 2. 3 2. 3 33 - --- 3.32. 2.222222.6% % 3 32 W. 3 2. 2

2. 3 2. 2. 3 33 23 3 % 3 2. 3. 3 s22. 3% U.S. Patent Jul. 9, 2013 Sheet 18 Of 35 US 8,480,637 B2

421 441

430

3 L 2. 420 22--> : . - - -3. - - 1------1------1------>3 & 3 32222222 3. --- 33-4402. % 2.

2 222222222222.222222,3 3. 3. a 3 450 21. a %------> 3 - 3.3 3--- 22222222222 3 3.a.3 2. 2 2 22.22, 3322 3.3 2.

23 %2. ------3 -1- 3 22 3 32 3. 32 % 3 2.----> 33 FIG. 8F

421 441

430 420

3 440 2%

32 y

3 450 2 3.3. 3 ---

233 - 22.

3 %23. 22323 2. 3 6 3 3 3 3 3 3N410a- 2.------> 2.:------2222222222, 2 -a- W 3 3. 2. 2. 22 3. 3. 2. -3

3222222222 3 322222222222 3.- - 3 - U.S. Patent Jul. 9, 2013 Sheet 19 Of 35 US 8,480,637 B2

445 N

T

nitri I E.

FIG. 8H

450

410

FIG. 8

U.S. Patent Jul. 9, 2013 Sheet 21 Of 35 US 8,480,637 B2

550

FIG. 8M

U.S. Patent Jul. 9, 2013 Sheet 23 Of 35 US 8,480,637 B2

& N Y

NSSSSSSSSSSSSSSSSSS W S. a

N S

&NS

SSSNTA, NSSSSSSSS NN SS N

550

FIG 8P U.S. Patent Jul. 9, 2013 Sheet 24 of 35 US 8,480,637 B2

FIG 9

FIG. 10 U.S. Patent Jul. 9, 2013 Sheet 25 Of 35 US 8,480,637 B2

as ...... SEM image of deep etched 190umX190um OpeningS. FIG 11

Optical Image O f front Surface Of nDS de WICe after ano diC bOn ding. FIG. 12 U.S. Patent Jul. 9, 2013 Sheet 26 of 35 US 8,480,637 B2

Optical image of inlet Channel OpeningS under bonded and lapped glass film. FIG. 13

FIG. 14 U.S. Patent Jul. 9, 2013 Sheet 27 Of 35 US 8,480,637 B2

U.S. Patent Jul. 9, 2013 Sheet 28 Of 35 US 8,480,637 B2

PCLOB9080 Wii. 844040 OOBOr B. Pass Rasagoons sov 27 in chooseoghoobs' SSix 3 so

FIG. 17 Man0Channel Ceiling & Floor Removal Solvent/Elchant Placeholder (substrate & Capping layer) Tungsten SiO, S.N. S. SIC, SICN, AU, BCB Warm H.0, Ge S0, SIN, SI, SIC, SICN, AL, BCB Warm H.0, CU SiO, S.N Si SIC, SICN Piranha AU SiO, S.N. S. SIC, SICM, BCB Aqua Regia Cr SiO, S.N Si SIC, SICN, BCB ChrOne EtChant TiN SiO, SiN. S. SIC, SICN, BCB Ammonia/PerOXide miX AI SiO, S.N. SI SIC, SICN HPO/HNO, AI SiO, S.N. SIC, SICM, BCB KOH PhOSphOSilicate glass S.N. W. SIC, SICN, St. Au, BCB | Dilute HF SiO, SiM, WSIC, Si SICN, AU, BCB | BOE Polymers S, SN, SIC, SICN, Oxide, Metal Organic Solvents, Piranha SiN Si, SiO, SIC, SICN Hot HPO, Si S.N. SIO, SIC, SICN Hot KOH F.G. 18 U.S. Patent Jul. 9, 2013 Sheet 29 Of 35 US 8,480,637 B2

620

U.S. Patent Jul. 9, 2013 Sheet 30 Of 35 US 8,480,637 B2

U.S. Patent Jul. 9, 2013 Sheet 31 Of 35 US 8,480,637 B2

915 FIG. 24 U.S. Patent Jul. 9, 2013 Sheet 32 Of 35 US 8,480,637 B2

FIG. 25

FIG. 26 U.S. Patent Jul. 9, 2013 Sheet 33 Of 35 US 8,480,637 B2

1160 U.S. Patent Jul. 9, 2013 Sheet 34 of 35 US 8,480,637 B2

FIG. 29

FIG. 30 U.S. Patent Jul. 9, 2013 Sheet 35 of 35 US 8,480,637 B2

Small Chip With All the Drug Contained Within the Macrochannels 2mm X 2mm X 1/2mm

Outlets EnCapsulation

Macrochannels - drug Contained Within FIG. 31 US 8,480,637 B2 1. 2 NANOCHANNELED DEVICE AND RELATED In certain embodiments, the nanochannel delivery device METHODS is made of a “sandwich' of materials, composed of a thin top layer, the horizontal nanochannels, and a thicker bottom CROSS-REFERENCE TO RELATED wafer. The thin top layer can house an array of microchannels APPLICATIONS that offer an inlet or outlet for diffusing molecules. It can also serve as the lid or ceiling for the nanochannels by providing This application claims priority to U.S. Provisional Patent the channels top surface. The thickerbottom wafer can house Application Ser. No. 61/114,687, filed Nov. 14, 2008, entitled an array of microchannels that offer a collateral outletorinlet. “Nanochanneled Device and Method of Use', and U.S. Pro Note that in the following, inlets are indicated in the bottom visional Patent Application Ser. No. 61/168,844, filed Apr. 10 wafer and outlets are indicated in the top layer, but this is not 13, 2009, entitled “Nanochanneled Device and Method of a limit of the invention. In certain embodiments, the Use', the entire disclosures of which are specifically incor nanochannels are fabricated by a sacrificial layer technique porated herein by reference. that provides Smooth Surfaces and precisely controlled This invention was made with government Support under 15 dimensions. The nanochannels can be formed in between the contract NNJ06HE06A awarded by NASA. The government two layers and connect the outlet microchannels with the has certain rights in this invention. array of inlet microchannels formed in the bottom wafer, additionally allowing thin surface layers to be applied to both BACKGROUND INFORMATION the top and the bottom surfaces independently, in order to optimize channel properties Such as Surface charge, hydro Considerable advances have been made in the field of phobicity, wetting and conductivity. Each inlet and outlet therapeutic agent (e.g. drug) delivery technology over the last microchannel can be connected to one, two, or more three decades, resulting in many breakthroughs in clinical nanochannels. The height, width, and length of the nanochan medicine. The creation of therapeutic agent delivery devices nel can be used to maintain a constant (Zero-order) delivery. that are capable of delivering therapeutic agents in controlled 25 By the help of nanofabrication, a nanochannel length of 10 ways is still a challenge. One of the major requirements for an nm or less is feasible. implantable drug delivery device is controlled release of In certain embodiments, the nanochannel delivery device therapeutic agents, ranging from Small drug molecules to is designed to yield high strength. This can be achieved by a larger biological molecules. It is particularly desirable to supporting structure obtained in the bottom side of the thick achieve a continuous passive drug release profile consistent 30 wafer. The structure can be composed by a regular mesh of with zero order kinetics whereby the concentration of drug in the bloodstream remains constant throughout an extended micrometric walls which create the side surfaces of larger delivery period. inlet macrochannels. Moreover, the top portion of the bottom wafer (in or on which nanochannels may be fabricated) can be These devices have the potential to improve therapeutic engineered to provide good mechanical stability. efficacy, diminish potentially life-threatening side effects, 35 improve patient compliance, minimize the intervention of The thickness of the Supporting layer underneath the healthcare personnel, reduce the duration of hospital stays, nanochannels can be optimized, and can be realized by con and decrease the diversion of regulated drugs to abusive uses. trolling the depth of the inlet microchannels and outlet mac Nanochannel delivery devices may be used in drug deliv rochannels or by selecting an SOI wafer with appropriate ery products for the effective administration of drugs. In 40 depth ofburied oxide layer. The materials and thickness oftop addition, nanochannel delivery devices can be used in other layers is also optimized for the attributes noted above. applications where controlled release of a Substance overtime Certain embodiments include a nanochannel delivery is needed. device comprising: an inlet microchannel; a nanochannel; and an outlet microchannel, wherein the inlet microchannel SUMMARY 45 and the outlet microchannel are in direct fluid communication with the nanochannel. In specific embodiments, the Embodiments of this invention comprise a nanochannel nanochannel is oriented parallel to the primary plane of the delivery device having nanochannels within a structure con nanochannel delivery device. In particular embodiments, a figured to yield high mechanical strength and high flow rates. flow path from the inlet microchannel to the nanochannel to Various fabrication protocols may be used to form the 50 the outlet microchannel requires a maximum of two changes nanochannel delivery device. Embodiments of the fabricated in direction. devices feature horizontal nanochannel lay-out (e.g., the In specific embodiments, the inlet microchannel has a nanochannel is parallel to the primary plane of the device), length, a width, and a depth; the outlet microchannel has a high molecule transport rate, high mechanical strength, length, a width, and a depth; and the nanochannel has a optional multilayered lay-out, amenability to select channel 55 length, a width, and a depth. In certain embodiments, the ratio lining materials, and possible transparent top cover. Based on of the nanochannel length to the inlet microchannel length is silicon microfabrication technology, the dimensions of the between 0.01 and 10.0, and the ratio of the nanochannel nanochannel area as well as concomitant microchannel areas length to the outlet microchannel length is between 0.01 and can be precisely controlled, thus providing a predictable, 10.0. In particular embodiments, the nanochannel length is reliable, constant release rate of drug (or other) molecules 60 greater than the inlet microchannel length and the nanochan over an extended time period. In certain embodiments, the nel length is greater than the outlet microchannel length. In nanochannel delivery device can be used to build a multilay specific embodiments, the ratio of the nanochannel length to ered nanochannel structure. Multilayered nanochannel struc either the inlet microchannel length or the outlet microchan tures can extend the limit of release rate range of a single layer nel length is between 0.2 and 5.0, between 0.3 and 3.0, nanochannel delivery device or system, and allow a wide 65 between 0.4 and 2.0, or between 0.5 and 1.0. In certain range of pre-defined porosity to achieve an arbitrary release embodiments, the nanochannel length is greater than the rate using any preferred nanochannel size. length, width, and depth of the outlet microchannel. In par US 8,480,637 B2 3 4 ticular embodiments, the inlet microchannel is in direct fluid macro channel comprises boundary walls that are generally communication with the outlet microchannel via a single perpendicular to the inlet Surface. In specific embodiments, nanochannel. the inlet macrochannel is formed by deep reactive- etch Certain embodiments include a nanochannel delivery ing. In particular embodiments, a primary axis of the outlet device comprising: an inlet microchannel; a nanochannel; an microchannel is perpendicular to a plane that is parallel to the outlet microchannel; and a fluid flow path from the inlet Substantially planar body. microchannel to the outlet microchannel, where the fluid flow Certain embodiments comprise an apparatus comprising a path requires a maximum of two changes in direction. In first nanochannel delivery device inserted into a capsule. In specific embodiments, the nanochannel is oriented parallel to particular embodiments, the first nanochannel delivery the primary plane of the nanochannel delivery device. In 10 device is installed perpendicular to the primary axis of the particular embodiments, the inlet microchannel and the outlet capsule. In particular embodiments, the capsule comprises a microchannel are in direct fluid communication with the septum. In certain embodiments, the septum comprises a nanochannel. self-sealing material. In specific embodiments, the septum Certain embodiments include a nanochannel delivery com comprises silicone rubber. In certain embodiments, the sep prising: a Substantially planar body comprising a first Surface 15 tum is configured to receive an injection of a therapeutic and a second Surface opposing the first Surface; a nanochannel agent. disposed within the Substantially planar body; an inlet micro Particular embodiments comprise a cap covering the sep channel in fluid communication with the nanochannel; and an tum. In certain embodiments, the cap comprises an orifice outlet microchannel in fluid communication with the configured to guide a needle towards the septum. In specific nanochannel. In particular embodiments, the inlet micro embodiments, the capsule comprises a cover extending over channel extends from the nanochannel to the first Surface and the first nanochannel delivery device. In particular embodi wherein the outlet microchannel extends from the nanochan ments, the cover comprises one or more orifices. In certain nel to second Surface. embodiments, the one or more orifices are sized so that they Certain embodiments include a nanochannel delivery do not limit diffusion of a therapeutic agent from the capsule device comprising: a plurality of inlet microchannels; a plu 25 during use. In certain embodiments, the cover is configured to rality of nanochannels; and a plurality of outlet microchan protect the first nanochannel delivery device from mechanical nels, where each inlet microchannel is in direct fluid commu damage. In particular embodiments, the cover is configured to nication with an outlet microchannel via a single protect the first nanochannel delivery device from incursion nanochannel. In particular embodiments, the nanochannel is by biological tissue structures after the capsule has been oriented parallel to the primary plane of the nanochannel 30 implanted in a living body. In certain embodiments, the cap delivery device, and/or an inlet microchannel and an outlet Sule comprises a first inner reservoir. In specific embodi microchannel are in direct fluid communication with a com ments, the first nanochannel delivery device is in fluid com mon nanochannel. In particular embodiments, individual munication with the first inner reservoir. inlet and outlet microchannels are arranged perpendicular to In specific embodiments, the capsule comprises a second a primary plane of the nanochannel delivery device; the plu 35 inner reservoir in fluid communication with a second rality of inlet microchannels form a first array; the plurality of nanochannel delivery device. In certain embodiments, the outlet microchannels form a second array; and the first array first and second inner reservoir are not in fluid communica and the second array are overlapping so that individual inlet tion with each other. In particular embodiments, the first and microchannels are distributed between individual outlet second inner reservoir are separated by a wall. In specific microchannels when viewed along a section taken perpen 40 embodiments, the first inner reservoir contains a first thera dicular to the primary plane. peutic agent and the second inner reservoir comprises a sec Certain embodiments include a nanochannel delivery ond therapeutic agent. In particular embodiments, the first device comprising: a Substantially planar body including: a nanochannel delivery is configured to diffuse a first therapeu length, a width, and a thickness, wherein the length and the tic agent at a first diffusion rate and the second nanochannel width are each greater than the thickness; an inlet Surface on 45 delivery device is configured to diffuse the second therapeutic a first side of the substantially planar body, wherein the inlet agent a second diffusion rate. surface is bounded by the length and the width of the substan In certain embodiments the volume of the first inner reser tially planar body; and an outlet Surface on a second side of Voir can be modified by replacing a first removable compo the substantially planar body. In particular embodiments, the nent of the capsule with a larger removable component. In outlet surface is bounded by the length and the width of the 50 particular embodiments, the first inner reservoir comprises a Substantially planar body, and the inlet Surface is Substantially coating compatible with a therapeutic Substance. In specific parallel with the outlet surface. Specific embodiments com embodiments, the capsule comprises an outer coating config prise a nanochannel disposed within the Substantially planar ured to prevent deleterious tissue encapsulation. In particular body, where the nanochannel comprises an inlet end and an embodiments, the capsule comprises a cylindrical shape. In outlet end; an inlet microchannel in fluid communication with 55 certain embodiments, the capsule comprises a disc shape. In the nanochannel; and an outlet microchannel in fluid commu certain embodiments, the capsule comprises a rectangular nication with the nanochannel, where the inlet microchannel Surface and an arched Surface. In specific embodiments, the and nanochannel are configured such that a first linear axis capsule comprises a uniform cross-section. can extend between the inlet surface and the inlet end of the In certain embodiments, the capsule comprises one or more nanochannel. In particular embodiments, the outlet micro 60 of the following materials: stainless steel, titanium, poly channel and nanochannel are configured such that a second etheretherkeytone, polysulfone, epoxy, silicone rubber, poly linear axis can extend between the outlet surface and the etherketoneketone, and thermoplastic polyurethane. In par outlet end of the nanochannel. In certain embodiments, a ticular embodiments, the capsule comprises an anchor primary axis of the inlet microchannel is perpendicular to a member. In certain embodiments, the anchor member is con plane that is parallel to the substantially planar body. Particu 65 figured to receive a Suture. In specific embodiments, the cap lar embodiments comprise an inlet macrochannel between Sule comprises a color coding to indicate a characteristic of the inlet surface and the inlet microchannel, where the inlet the capsule or the nanochannel delivery device. In particular US 8,480,637 B2 5 6 embodiments, the color coding indicates a characteristic of a microchannels and inlet macrochannels. In particular therapeutic agent contained within the capsule. In specific embodiments of the method, each nanochannel is between embodiments the capsule comprises a translucent ortranspar approximately one and ten nanometers deep, between ent cover extending over the first nanochannel delivery approximately ten and twenty nanometers deep, between device. approximately twenty and thirty nanometers deep, between Certain embodiments include a method of fabricating a approximately thirty and forty nanometers deep, or between nanochannel delivery device. In particular embodiments, the approximately forty and two hundred nanometers deep. method comprises: providing a first Substrate; forming a plu In certain embodiments of the method, the first sacrificial rality of nanochannels in the first Substrate; forming a plural material can be subsequently removed by selective etching. In ity of inlet microchannels in the nanochannels of the first 10 particular embodiments, the first sacrificial material is tung Substrate; providing a second Substrate; forming a plurality of sten. In specific embodiments, the second sacrificial material outlet microchannels in the second Substrate; and coupling can be subsequently removed by selective etching. In certain the second substrate to the first substrate, wherein each inlet embodiments of the method, the second sacrificial material is microchannel is in direct fluid communication with a selected from the group consisting of tungsten, , nanochannel. 15 doped glass, and undoped glass. In particular embodiments, In particular embodiments of the method, the first substrate the second sacrificial material is filled into the plurality of comprises a silicon-on-insulator wafer. In certain embodi inlet microchannels so that the second sacrificial material ments, the height of each nanochannel is between approxi extends above the top of the inlet microchannels and is pla mately one and ten nanometers. In specific embodiments, the narized by chemical-mechanical planarization (CMP). height of each nanochannel is between approximately ten and In particular embodiments of the method, the capping layer twenty nanometers, between approximately twenty and thirty is selected from Silicon nitride, silicon oxide, silicon carbo nanometers, between approximately thirty and fifty nanom nitride, silicon carbide, and silicon. In certain embodiments, eters, between approximately fifty and one hundred nanom the capping layer comprises multiple depositions of materials eters, or between approximately one hundred and two hun comprising tensile and compressive stresses such that the net dred nanometers. In certain embodiments the second 25 capping layer stress is tensile. In certain embodiments of the Substrate comprises a sacrificial release layer of indium tin method, the capping layer is between approximately 0.5 and oxide film on silicon. Particular embodiments further com 1.0 microns thick, between approximately 1.0 and 2.0 prise depositing a glass film on the second Substrate prior to microns thick, between approximately 2.0 and 4.0 microns forming the plurality of inlet microchannels in the second thick, or between approximately 4.0 and 10.0 microns thick. Substrate. In specific embodiments, the second Substrate com 30 In specific embodiments, the capping layer is greater than prises a glass wafer and the glass wafer is bonded to the first 10.0 microns thick. substrate and the glass wafer is ground to reduce the thickness Particular embodiments comprise a method of fabricating prior to forming the plurality of outlet microchannels. a nanochannel delivery device, where the method comprises: Certain embodiments include a method of fabricating a providing a first Substrate; forming a plurality of nanochan nanochannel delivery device where the method comprises: 35 nels on a first side of the first substrate; filling in the plurality providing first Substrate; forming a plurality of nanochannels of nanochannels with a sacrificial material; coupling an initial on the first substrate; filling in the plurality of nanochannels capping layer to the first side of the first Substrate; forming a with a first sacrificial material; forming a plurality of inlet plurality of inlet microchannels in the capping layer, prepar microchannels in the first substrate; filling in the plurality of ing a second Substrate with a bonding layer, coupling the inlet microchannels with a second sacrificial material; form 40 second substrate to a second side of the first substrate; remov ing a capping layer that covers the plurality of nanochannels; ing a first portion of the second Substrate; providing an addi forming a plurality of outlet microchannels in the capping tional capping layer to the second Substrate; forming a plu layer; removing the first sacrificial material from the plurality rality of outlet microchannels in the second Substrate; and of nanochannels; and removing the second sacrificial mate removing the sacrificial material to open the plurality of rial from the plurality of inlet microchannels. 45 nanochannels. In particular embodiments of the method, an inlet micro In certain embodiments of the method, the second substrate channel is arranged perpendicular to a primary plane of the comprises a release layer, and the release layer can be selec first Substrate. In specific embodiments, an outlet microchan tively removed to cause separation of the second Substrate nel is arranged perpendicular to a primary plane of the first from the first substrate. In particular embodiments of the substrate. In certain embodiments of the method, an inlet 50 method, an outlet microchannel is in direct fluid communi microchannel is in direct fluid communication with a cation with the a nanochannel. In certain embodiments, the nanochannel. In particular embodiments, an outlet micro first Substrate comprises a silicon-on-insulator wafer com channel is in direct fluid communication with a nanochannel. prising an internal oxide layer. In specific embodiments, In certain embodiments of the method, the first substrate forming the plurality of inlet microchannels comprises etch comprises a silicon-on-insulator wafer comprising an internal 55 ing material from the capping layer, and the etching is termi oxide layer. In particular embodiments, the inlet and outlet nated at the internal oxide layer. microchannels are patterned using a photolithography pro In certain embodiments, forming a plurality of inlet mac cess. In certain embodiments, forming the plurality of inlet rochannels comprises etching material from a back side of the microchannels comprises etching material from the first Sub first Substrate, and the etching is terminated at the internal strate, and the etching is terminated at the internal oxide layer. 60 oxide layer. In particular embodiments, the removal of the In particular embodiments of the method, forming a plurality internal oxide layer after etching material to form the inlet of inlet macrochannels comprises etching material from a microchannel and inlet macrochannels opens a pathway back side of the first substrate, and the etching is terminated at between the inlet microchannels and inlet macrochannels. the internal oxide layer. In certain embodiments, each nanochannel is formed In certain embodiments the removal of the internal oxide 65 between approximately one and ten nanometers deep, layer after etching material to form the inlet microchannel between approximately ten and twenty nanometers deep, and inlet macrochannels opens a pathway between the inlet between approximately twenty and thirty nanometers deep, US 8,480,637 B2 7 8 between approximately thirty and forty nanometers deep, or meaning of “one or more' or “at least one.” The term “about between approximately forty and two hundred nanometers means, in general, the stated value plus or minus 5%. The use deep. of the term 'or' in the claims is used to mean “and/or unless In particular embodiments, the sacrificial material can be explicitly indicated to refer to alternatives only or the alter Subsequently removed by selective etching. In specific native are mutually exclusive, although the disclosure Sup embodiments, the sacrificial material is tungsten. In certain ports a definition that refers to only alternatives and “and/or.” embodiments, the initial capping layer is silicon nitride The terms “comprise' (and any form of comprise, Such as deposited by plasma enhanced chemical vapor deposition. In “comprises” and “comprising”), “have (and any form of certain embodiments of the method, the initial capping layer have, such as “has and “having), “include’ (and any form of is between approximately 0.01 and 0.5 microns thick, 10 between approximately 0.5 and 1.0 microns thick, between include, such as “includes” and “including”) and “contain' approximately 1.0 and 2.0 microns thick, between approxi (and any form of contain, such as "contains and “contain mately 2.0 and 4.0 microns thick, or between approximately ing') are open-ended linking verbs. As a result, a method or 4.0 and 10.0 microns thick. In specific embodiments of the device that “comprises.” “has.” “includes” or “contains” one method, the initial capping layer is greater than 10.0 microns 15 or more steps or elements, possesses those one or more steps thick. In certain embodiments of the method, the initial cap or elements, but is not limited to possessing only those one or ping layer is selected from silicon nitride, silicon oxide, sili more elements. Likewise, a step of a method or an element of con carbonitride, silicon carbide, and silicon. In particular a device that “comprises.”“has “includes” or “contains one embodiments, the initial capping layer comprises multiple or more features, possesses those one or more features, but is depositions of materials comprising tensile and compressive not limited to possessing only those one or more features. stresses such that the net capping layer stress is tensile. In Furthermore, a device or structure that is configured in a certain embodiments of the method, the bonding layer is certain way is configured in at least that way, but may also be selected from the group consisting of benzocyclobutene, sili configured in ways that are not listed. con oxide, copper, doped glass, gold and gold alloys. The term “inlet microchannel’ is defined as a microchan In certain embodiments, the method of coupling the second 25 nel through which a molecule travels prior to entering a substrate to the first substrate is selected from the group nanochannel in a nanochanneled delivery device. consisting of anodic bonding, fusion bonding, and thermo The term “outlet microchannel’ is defined as a microchan compression bonding. nel through which a molecule travels immediately prior to Particular embodiments include a nanochannel delivery exiting a nanochanneled delivery device. device comprising: a plurality of inlet microchannels, where 30 The term "nanochannel’ is defined as a channel with a each of the inlet microchannels has a length, a width, and a cross-section having at least one dimension (e.g. height, depth, and where the inlet microchannellength is greater than width, diameter, etc.) that is less than 200 nm. the inlet microchannel width and depth; a plurality of outlet The term "macrochannel is defined as a channel with a microchannels, where each of the outlet microchannels has a cross-section having a maximum dimension (e.g. height, length, a width, and a depth; and a plurality of nanochannels 35 width, diameter, etc.) that is greater than about 10 um. in fluid communication with the plurality of inlet microchan Other objects, features and advantages of the present nels and outlet microchannels. In certain embodiments, the invention will become apparent from the following detailed plurality of inlet microchannels are arranged so that the inlet description. It should be understood, however, that the microchannel width and depth define a first plane that is detailed description and the specific examples, while indicat parallel to the primary plane of the nanochannel delivery 40 ing specific embodiments of the invention, are given by way device; and the plurality of outlet microchannels are arranged of illustration only, since various changes and modifications so that the outlet microchannel width and depth define a within the spirit and scope of the invention will be apparent to second plane that is parallel to the primary plane of the those skilled in the art from this detailed description. nanochannel delivery device. Particular embodiments include a method of treating a 45 BRIEF DESCRIPTION OF THE FIGURES condition of a person, the method comprising: providing a nanochannel delivery device as described herein; providing a FIGS. 1A-1J are schematic views of a manufacturing pro reservoir in fluid communication with the nanochannel deliv cess according to an exemplary embodiment. ery device; providing a Substance in the reservoir, where the FIGS. 2A-2E are perspective views of a first portion of a Substance is configured to treat the condition; and adminis 50 nanochannel delivery device during the manufacturing pro tering the Substance to the person via the nanochannel deliv CCSS, ery device. In particular embodiments of the method, the FIGS. 3A-3F are perspective views of a second portion of Substance is selected from the group consisting of leuprolide, a nanochannel delivery device during the manufacturing pro , laptinib, buprenorphine, interferon, and Zidovu CCSS, dine. In certain embodiments, the condition is selected from 55 FIG. 3G is a partial perspective view of a nanochannel the group consisting of , , delivery device with representative dimensions labeled. dependency, giant angioblastoma and HIV. In particular FIG. 4A-4L are schematic views of a manufacturing pro embodiments of the method, administering the Substance to cess according to an exemplary embodiment. the person via the nanochannel delivery device comprises FIGS. 5A-5H are schematic cross-section views of a Subcutaneously inserting the nanochannel delivery device 60 nanochannel delivery device during the manufacturing pro into the person. cess according to an exemplary embodiment. In the following, the term “coupled' is defined as con FIGS. 6A-6J are schematic views of a manufacturing pro nected, although not necessarily directly, and not necessarily cess according to an exemplary embodiment. mechanically. FIG. 7 is a cross-sectional side view of a schematic of an The use of the word “a” or “an' when used in conjunction 65 exemplary embodiment of a nanochannel delivery device. with the term “comprising in the claims and/or the specifi FIGS. 8A-8I are schematic views of a manufacturing pro cation may mean "one.” but it is also consistent with the cess according to an exemplary embodiment. US 8,480,637 B2 10 FIGS. 8J-8P are orthogonal and perspective views of ing a nanochannel delivery device. Specific dimensions are exemplary embodiments during various stages of the manu provided for purposes of illustration only, and it is understood facturing process. that other exemplary embodiments may comprise different FIG. 9 is a perspective view of a nanochannel delivery dimensions. device according to an exemplary embodiment. In one exemplary embodiment manufactured according to FIG. 10 is a cross-sectional side view of a schematic of an this protocol, the top layer is a cover of a 5 um thick evapo exemplary embodiment of a nanochannel delivery device. FIG. 11 is a scanning electron microscope image of a rated glass layer and the bottom wafer is a 4 inch SOI wafer portion of a nanochannel delivery device according to an with a 30 um device layer, and a 500 umbulk layer, so that the exemplary embodiment. Supporting layer under the nanochannels has 30 umthickness. FIG. 12 is an optical image of a bonded wafer of a 10 In this exemplary structure, the inlet and outlet microchannels nanochannel delivery device according to an exemplary are 5 um by 5 um, and the in-plane dimension of each embodiment. nanochannel is 5 um by 5 um. The space between adjacent FIG. 13 is an optical image of a front Surface of a nanochan openings (e.g., the distance between adjacent nanochannels) nel delivery device according to an exemplary embodiment is 2 um. The inlet macrochannel under the Support network is after polishing. 15 approximately 200 um by 200 um up through the 500 um FIG. 14 is a scanning electron microscope image of a thick bulk layer. portion of a nanochannel delivery device according to an A general overview of this method of manufacturing will exemplary embodiment. first be presented, followed by a more detailed discussion of FIG. 15 is an optical image of a portion of a nanochannel the features comprised in the nanochannel delivery device. In delivery device according to an exemplary embodiment after this embodiment, fabrication of the nanochannel delivery polishing. device does not utilize chemical mechanical polishing FIG.16 is scanning electron microscope image of a portion (CMP), and the microfabrication protocol comprises the fol of a nanochannel delivery device according to an exemplary lowing steps. Starting with a SOI (silicon on insulator) wafer embodiment. (see FIG.2A), a hard mask layer such as silicon nitride film or FIG.17 is scanning electron microscope image of a portion 25 LTO(low temperature oxidation) film that will protect under of a nanochannel delivery device according to an exemplary neath silicon during thermal oxidation process is deposited. If embodiment. silicon nitride is used, a silicon dioxide pad layer may be FIG. 18 is a table of materials that may be used in exem plary embodiments of manufacturing processes. deposited before nitride deposition. As an alternative, the FIG. 19 is an exploded perspective view of a capsule and a bottom substrate can also be a silicon wafer instead of SOI if nanochannel delivery device according to an exemplary 30 the etching process rates are well characterized. In this case, embodiment. the etching depth is controlled by timing. FIG. 20 is an assembled perspective view of the embodi The nanochannel areas can then be patterned on the mask ment of FIG. 19. layer using photolithography process. (see FIGS. 1(a) and FIG. 21 is an assembled perspective view of a capsule 2B), and the mask materials on nanochannel areas are selec according to an exemplary embodiment. 35 tively removed but do not affect underneath silicon. A com FIG.22 is an exploded perspective view of the embodiment bination of dry etching, and short time wet etching may be of FIG. 21. applied for this purpose. Then a silicon dioxide film (with a FIG. 23 is an exploded perspective view of a capsule and a thickness that is well-controlled) can be deposited on bare nanochannel delivery device according to an exemplary silicon area by thermal oxidation. In this embodiment, the embodiment. 40 thickness of the oxidation layer is used to define the height of FIG. 24 is an exploded perspective view of a capsule and a nanochannels, and the mask layer is stripped. nanochannel delivery device according to an exemplary A mask layer Suitable for deep silicon etching can then be embodiment. deposited. The mask layer should be able to be patterned, and FIG. 25 is an assembled perspective view of a capsule have a high selectivity to silicon during deep silicon etching according to an exemplary embodiment. 45 process. Depending on the technique for deep silicon etching, FIG. 26 is an exploded perspective view of the embodiment a layer of silicon oxide, photoresist, or metal film may be of FIG. 25. used. FIG. 27 is an assembled perspective view of a capsule In this embodiment, the inlet microchannels are patterned according to an exemplary embodiment. on the mask layer, and the inlet microchannels are etched FIG.28 is an exploded perspective view of the embodiment 50 down to the oxide layer of the SOI wafer by deep RIE (Reac of FIG. 27. tive Ion Etch) or ICP (Inductive Coupled Plasma) technique, FIG. 29 is a perspective view of a capsule according to an as shown FIGS. 1(b) and . If a silicon wafer is used, the exemplary embodiment. etching depth is determined by etching rate and time. FIG. 30 is a perspective view of a capsule according to an The inlet macrochannels (the large openings from the exemplary embodiment in an installed location. 55 back) are laid out and etched to the oxide layer of SOI wafer, FIG. 31 is a perspective view and a section view of a as shown in FIGS. 1 (c) and 2D, and the exposed oxide areas capsule according to an exemplary embodiment. are cleaned by HF solution. (see FIGS. 1 (d) and 2E). To fabricate the top cover of the nanochannel delivery devices in DETAILED DESCRIPTION OF ILLUSTRATIVE this embodiment, starting with a Support wafer (e.g., a silicon EMBODIMENTS 60 wafer), a sacrificial layer is deposited. (see FIGS. 1(e), 1(f) and 3A). This sacrificial layer (e.g., indium tin oxide (ITO)), Protocol 1 is selected so that it can be removed in a solution that is safe for silicon and top cover materials. Bonded Capping Layer The top cover of the nanochannel delivery devices is 65 deposited on the sacrificial layer (see FIGS. 1 (g) and 3B), and FIGS. 1a-1j. 2A-2E, and 3A-3G provide illustrations of the outlets are patterned on the structure, as shown in FIGS. steps performed in an exemplary first method of manufactur 1(h) and 3C). As an alternative, a lift-off technique may be US 8,480,637 B2 11 12 applied for the cases of sputtered glass or e-beam evaporated understood, the designations “upper” and “lower are used glass. The materials may be any suitable material, e.g. spin only for purposes of clarification in the description of the on-glass, sputtered glass, e-beam evaporated glass, ITO-glass figures, and do not dictate the relationship of components sandwich, silicon, polymer, etc. The materials may include during use of the device. As shown in FIGS. 3D and 3E, upper glass and glass materials known to those skilled in the art to 5 portion 45 and lower portion 40 are bonded together (through, bond to silicon by specific means, e.g., anodic bonding or e.g., anodic bonding or Si-Sidirect bonding or intermediate fusion bonding. The materials should be able to bond to layer aided bonding). Support substrate 55 is removed from silicon by certain means. For instance of glass, anodic bond upper portion 45, and nanochannel delivery device 100 is ing can be applied. A spin-on-glass layer may also applicable. completed, as shown in FIGS. 3F and 3G. The embodiment Depending on the Surface quality, a planarization process 10 shown in FIG. 3G comprises optional tapered surfaces in the may be needed. transitions between outlet microchannels 70 and nanochan The structure wafer and the top cover are bonded together nels 25, as well as between nanochannels 25 and inlet micro by a technique Such as anodic bonding or Si-Sidirect bond channels 30. ing or intermediate layer aided bonding, as shown in FIGS. As shown in FIG. 3G, nanochannels 25 lie in a plane 1(c), 3D, and 3E, and the support wafer of top cover is 15 parallel to the primary plane of nanochannel delivery device removed (as shown in FIGS. 1(j) and 3F). Finally, the indi 100 (e.g., the plane defined by the larger dimensions in this vidual nanochannel delivery devices are obtained by dicing example, L and W of nanochannel delivery device 100). the wafer, and cleaning. Such a configuration allows for the length of nanochannel 25 In another exemplary embodiment manufactured accord (e.g., approximately the distance between adjacent outlet 70 ing to this protocol, while keeping the bottom silicon Sub and inlet 30) and the height and width of the nanochannel to strate is the same 4 inch SOI wafer with a 30 um device layer be varied without varying the length L, width W, and thick and a 500 umbulk layer as that mentioned in above embodi ness T of nanochannel delivery device 100. The thickness T of ment, the top layer is a 10um thick glass film. The 10um thick nanochannel delivery device 100 can therefore be based on glass film is manufactured by thinning a thicker glass layer. other criteria (such as mechanical integrity) rather than the To make this thin film, a 100 um to 500 um thick glass wafer 25 need to control the flow of a substance being delivered via is bonded to the structural silicon Substrate. A planarization nanochannel delivery device 100. technique Such as backgrinding, or lapping, or CMP, or The embodiments shown in FIGS. 3A-3G also provide for chemical etching, or dry etching is then applied to thin the each outlet 70 to be in fluid communication with any inlet 30 glass layer until the designed thickness Such 10um is reached. via a single nanochannel 25. Sucha configuration can provide The outlets are then patterned on the thinned glass film, and 30 for greater control over the diffusion of a substance being etched down to the underneath silicon surface to open the delivered via nanochannel delivery device 100. For example, outlets. In this exemplary structure, the inlet and outlet micro the diffusion rate through nanochannel delivery device 100 is channels are 5 um by 5 um, and the in-plane dimension of more closely related to the dimensions of nanochannel 25, as each nanochannel is 5um by 5um. The space between adja compared to configurations that have numerous nanochan cent openings (e.g., the distance between adjacent nanochan 35 nels in fluid communication with a single extended inlet. In nels) is 2 Lum. The inlet macrochannel under the Support Such configurations, the inlet (rather than the nanochannel) network is 200 um by 200 um up through the 500 um thick may become a restriction on flow and limit the ability to bulk layer. control the flow by varying the dimensions of the nanochan Referring specifically now to FIGS. 2A-2E and 3A-3F, a nel. more detailed view of the features of nanochannel delivery 40 As shown in the detailed view of FIG. 3G (not to scale), device 100 is provided. Referring initially to FIG. 2A, an SOI nanochannel 25 comprises a length nL, a width nW and a wafer 10 comprises a top layer 15 over a substrate 20 and height nH. Outlet microchannel 70 comprises a length oL, a separated by an oxide layer 35. As shown in FIG. 2B, a series width oW, and a height oH. In addition, inlet microchannel 30 of nanochannels 25 are formed using a pattern mask in top comprises a length iL, a width iW and a height iH. As shown layer 15. One or more inlet microchannels 30 is formed using 45 in FIG. 3G, the “length” of each channel is measured along a pattern mask in each nanochannel 25, as shown in FIG. 2C, the path that a molecule would travel as it moves from inlet exposing an oxide layer 35 between the substrate 20 and the microchannel 30, through nanochannel 25, and out through top layer 15. For purposes of clarity not all features, for outlet microchannel 70. In certain embodiments oL=4 um, example inlet microchannels 30, are labeled in the figures. oW=5um, oH=5 um while nH=50 nm, nW-4 um, and nL=5 As shown in FIG. 2D, a portion of substrate 20 is removed 50 um and oL=30 um, oW=5um, oH=5um. using a pattern mask from below the oxide layer 35. Oxide In certain embodiments, the ratio of oL/nL or iL/nL can be layer 35 is then removed (as shown in FIG. 2E), and inlet 0.1, 0.2,0.3, 0.4,0.5,0.6,0.7, 0.8, 0.9, 1.1, 1.2, 1.3, 1.4, 1.5, microchannels 30 are formed to allow passage of material 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, through the substrate 20 and top layer 15. At this stage, the 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, lower portion 40 of nanochannel delivery device 100 is com 55 4.4, 4.5, 4.6, 4.7, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, plete. 5.9, 6.0, 6.1, 6.2, 6.3, 6.4., 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, Referring now to FIGS. 3A-3F, the fabrication of the upper 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, portion 45 of nanochannel delivery device 100 begins with a 8.7, 8.8, 8.9, 9.0, 9.19.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, sacrificial layer 50 deposited on a support substrate 55. In 20, 30, 4050, 60, 70, 80,90, or 100. addition, an additional layer 60 (e.g., spin-on-glass, sputtered 60 glass, e-beam evaporated glass, ITO-glass sandwich, silicon, Protocol 2 polymer, etc.) may be used in processes utilizing a lift-off technique, as shown in FIG. 3B. Exit microchannels 70 are Multilayered Structure with Bonded Capping Layer formed in sacrificial layer (and additional layer 60, ifutilized) as shown in FIG. 3C. 65 In a second embodiment, a multilayered nanochannel At this stage, upper portion 45 is ready to be bonded to structure can be fabricated by modifying the above-described lower portion 40 of nanochannel delivery device 100. It is protocol 1. This embodiment comprises the following steps. US 8,480,637 B2 13 14 Starting with a SOI (silicon on insulator) silicon wafer, a cover can be removed (See FIG. 4(1)), and the devices silicon dioxide layer (with a thickness that is well-controlled) obtained by dicing the wafer and cleaning. is deposited by thermal oxidation. The thickness of the oxi dation layer can be used to define the height of nanochannels. Protocol 3 As an alternative, the bottom Substrate can also be silicon wafer instead of SOI if the etching process rates are well Monolithically Fabricated Capping Layer characterized. The nanochannel areas can be patterned on the oxide layer using photolithography process. As a third embodiment, a nanochannel structure can be The silicon oxide on non-nanochannel areas can be selec fabricated monolithically (e.g., without bonding) and option 10 ally utilizing CMP in the process. This exemplary microfab tively removed but not affect the oxide on nanochannel area. rication protocol comprises the following steps as shown in (See FIG. 4(a)). A polysilicon structure layer can be depos FIGS. SA-SH. ited on the top of oxide nanochannel spacing layer. (see FIG. Specific dimensions are provided for purposes of illustra 4(b)). A second defined thickness oxide layer can be depos tion only, and it is understood that other exemplary embodi ited again, and the nanochannel areas can be patterned on the 15 ments may comprise different dimensions. In this embodi oxide layer using photolithography process. The siliconoxide ment, the top layer is approximately 2 um of deposited silicon on non-nanochannel areas can be selectively removed but do nitride. This embodiment also comprises a bottom wafer that not affect the oxide on nanochannel area. (See FIG. 4(c)). is a 8 inch SOI wafer with a 30 um device layer, and a 725um This process finishes the second layer of nanochannels. The bulk layer, so that the Supporting layer under the nanochan previous two steps can be repeated to achieve desired number nels has 30 Lum thickness. In this exemplary structure, the of layers. openings for the inlet and outlet microchannels are 3 um by 5 As an alternative to the previous steps, the silicon oxide um, and the in-plane dimension of each nanochannel is 3 um nanochannel spacing layer and multilayer structure layer may by 5um. The space between adjacent microchannel openings also use other materials. For example, an aluminum film as is 2 Lim. As in previously-described embodiments, the inlet nanochannel spacing layer, and evaporated glass film as mul 25 macrochannel under the Support network is approximately tilayer structure layers. 200 um by 200 um up through the 725 um thick bulk layer. A first mask layer Suitable for deep silicon etching can be Starting with an SOI (silicon on insulator) wafer 210, a deposited. The mask layer should be able to be patterned, and nanochannel spacing layer 220 (with a thickness that is well have high selectivity to silicon during deep silicon etching controlled, for example, +5% over the relevant portion of SOI process. Depending on the technique for deep silicon etching, 30 wafer 210) is deposited. The thickness of spacing layer 220 can be used to define the height of the nanochannels. This a layer of silicon oxide, photoresist, or metal film may be spacing layer 220 is a sacrificial layer, and the material will be used. removed in a Subsequent step, so the silicon Surface immedi The inlet microchannels are patterned on the first mask ately under it is the “floor of the eventually formed layer, and a second mask layer is deposited on the top of first 35 nanochannels. The spacing material should have a high wet mask layer. The inlet microchannels are patterned on the both etch selectivity to other materials in the nanochannel delivery first and second mask layers. The outlet microchannels are device (nl)D). As an example, a thin film oftungsten, germa etched down to a certain depth close to oxide layer of the SOI nium, or silicon oxide can be used for the nanochannel spac wafer, and the second mask layer is stripped to expose the first ing layer 220. mask layer. The outlet microchannel is etched through mul 40 As shown in FIG.5A, a capping layer 230 is deposited over tiple layers of the nanochannel spacing layer and structure the nanochannel spacing layer 220. Capping layer 230 will layer. A combination of wet etching and DRIE may be ultimately be the "ceiling of the nanochannels. Silicon applied. This will also etch the inlet down to the insulator nitride, silicon oxide, silicon carbide, or other material which layer of SOI wafer. (See FIG. 4(d)). If a silicon wafer is used, has a high etch selectivity to the material for spacing layer 220 the etching depthis determined by etching rate and time. Then 45 may be used for capping layer 230. the inlet macrochannels on the back are laid out and etched to A mask layer (not shown) Suitable for deep reactive-ion the oxide layer of SOI wafer (see FIG.4(e)), and the oxide on etching (DRIE) is deposited, and the inlet microchannels 240 the exposed areas is cleaned. (See FIG. 4(f)). are patterned on the mask layer using photolithography. As To fabricate the top cover of the nanochannel delivery shown in FIG. 5B, the DRIE process(es) etch microchannels devices, starting with a Support wafer (e.g., a silicon wafer), a 50 240 through the capping layer 230 and spacing layer 220 and sacrificial layer is deposited. (See FIG. 4(h)). This sacrificial silicon down to the buried oxide layer 250 of SOI wafer 210. layer is selected so that it can be removed in a solution that is The mask layer can then be removed. safe for silicon and top cover materials. The top cover of the As shown in FIG. 5C, inlet microchannels 240 are filled nanochannel delivery device is deposited on the Supporting with a fill material 260 that can be polished by CMP or etched. 55 Non-limiting examples of fill material 260 include copper, wafer and the inlet microchannels are etched. A lift off tech tungsten, polysilicon, or phosphosilicate glass, each depos nique may be applied for certain cases. (See FIG.4(ii)). The ited by techniques known in the art. Fill material 260 should materials may include, for example, spin-on-glass, sputtered have a wet etch with high selectivity to silicon and the mate glass, e-beam evaporated glass, ITO-glass sandwich, silicon, rial of capping layer 230. In this exemplary embodiment, fill etc. The materials should be able to bond to silicon by some 60 material 260 only needs to fill in the top of inlet microchan means. For instance, a transparent glass layer can be depos nels 240. A CMP or etch back process can be used to remove ited by e-beam evaporation. A spin-on-glass layer may also the excess fill material 260 that extends above or outside of usable. Depending on the Surface quality, a planarization may inlet microchannels 240. The surface of the remaining fill be needed. The structure wafer from the previous step and the material 260 should be above the level of spacing layer 220. top cover can be bonded together by a technique Such as 65 Referring now to FIG. 5D, additional material may be anodic bonding or Si Si direct bonding or intermediate deposited onto capping layer 230. The areas of capping layer layer aid bonding. (See FIG. 4(k)). The support wafer of top 230 and spacing layer 220 above and between the inlet micro US 8,480,637 B2 15 16 channels 240 can be patterned using a photolithography pro designed to lay-out both inlet microchannels and outlet cess. The spacing layer 220 and capping layer 230 outside of microchannels on the same layer, and the nanochannel length the inlet nanochannels 240 (e.g., regions 221 and 231) can be is defined by the spacing between adjacent inlet and outlet etched to or slightly below the silicon surface. microchannels. The mask layer is patterned using the new Referring now to FIG. 5E, a final capping layer 270 is 5 mask by standard photolithography process. The mask mate deposited over the entire surface of wafer 210 to provide rials on open areas are selectively removed. Then a KOH wet structural rigidity and seal the sidewalls of the nanochannel etching is applied to form openings with the slope wall, and areas. Using a photolithography process, outlet microchan the mask layer is stripped. (See FIG. 6(b)). nels 280 can be patterned and etched through capping layers A mask layer Suitable for deep silicon etching can be 230,270 and optionally through spacing layer 220 into silicon 10 deposited. The mask layer should be able to be patterned, and 210 for additional process latitude. As shown in FIG. 5F, a protective layer 275 is deposited over capping layer 270 and have a high selectivity to silicon during deep silicon etching outlet microchannels 280. process. Depending on the technique for deep silicon etching, Referring now to FIG.5G, wafer 210 can then be inverted a layer of silicon oxide, photoresist, metal film, or other and large openings for inlet macrochannels 245 on the back of 15 Suitable material may be used. wafer 210 can be formed by DRIE down to the buried oxide The outlet microchannels are patterned on the mask layer layer 250 of wafer 210. As shown in FIG. 5H, sacrificial and and the outlet micro channels are etched down to the oxide protective layers used during processing (e.g. spacing layer layer of the SOI wafer by a suitable technique, for example a 220, fill material 260, capping layer 270, and portions of deep RIE or ICP technique. (See FIG. 6(c)). If a silicon wafer oxide layer 250) are removed by appropriate processes 20 is used, the etching depth can be determined by etching rate known in the art. As shown in FIG. 5H, when spacing layer and time. 220 is removed, nanochannels 205 are formed. The wafers The inlet macrochannels from the back are laid out and can then be diced to get individual nanochannel delivery etched to the oxide layer of the SOI wafer, and the exposed devices. oxide areas are cleaned by HF solution. (See FIG. 6(d)). To As illustrated in this embodiment, nanochannels 205 are in 25 fabricate the top cover of the nanochannel delivery devices, direct fluid communication withinlet microchannels 240 and starting with a Support wafer (e.g., silicon wafer), a sacrificial outlet microchannels 280. Specifically, inlet microchannels layer is deposited. (See FIG. 6(e, f)). This sacrificial layer 240 and nanochannels 205 are directly connected so that a (e.g. ITO), is selected so that it can be removed in a solution fluid exiting an inlet microchannel will immediately enter the that is safe for silicon and top cover materials. nanochannel without flowing through an intermediate body. 30 The top cover of the nanochannel delivery devices is As a variant of this protocol, and in analogy to protocol 2 deposited on the sacrificial layer. (See FIG. 6(g)), and the above, a multilayered structure can be built by repeated appli outlets are patterned on the structure. (See FIG. 6(h)). As an cation of the monolithic top layer process. A plurality of alternative, a lift-off technique may be applied for the cases of capping layer 230 and spacing layer 220 pairs can be depos sputtered glass or e-beam evaporated glass. In certain ited. The inlet microchannels can be etched through all layers 35 embodiments, the materials may be spin-on-glass, sputtered down to the buried oxide and filled with fill material 260 and glass, e-beam evaporated glass, ITO-glass sandwich, silicon, polished as above. The final capping layer 270 can be applied polymer, etc. The materials should be able to bond to silicon and outlet microchannels 280 etched as above. by certain means. For instance of glass, anodic bonding can be applied. A spin-on-glass layer may also applicable. Protocol 4 40 Depending on the Surface quality, a planarization process may be needed. Varying the Length of Nanochannels The structure wafer from step (6) and the top cover can be bonded together by a technique Such as anodic bonding or In certain embodiments, Protocol 1 can be modified to Si Si direct bonding or intermediate layer aided bonding. make a nanochannel delivery device with different a 45 (See FIG. 6(i)). The support wafer of top cover is removed nanochannel length while keep other features unchanged. An (See FIG. 6(f)), and the devices are obtained by dicing the exemplary microfabrication protocol comprises the follow wafer, and cleaning. ing steps. If the preferred length of nanochannel is less than 500 nm, Starting with a SOI (silicon on insulator) wafer, a hard a nanofabrication technique Such as e-beam or nanoimprint mask layer such as silicon nitride film or LTO (low tempera- 50 may be applied. Isotropic silicon etching technique may also ture oxidation) film that will protect the underneath silicon be applied. A schematic structure view of a short nanochannel during thermal oxidation process is deposited. If silicon delivery device is shown in FIG. 7. As shown in FIG. 7, inlet nitride is used, a silicon dioxide pad layer may be deposited microchannel 340 has a portion 341 that is flared or tapered before nitride deposition. As an alternative, the bottom sub proximal to nanochannel 305. Similarly, outlet microchannel strate can also be silicon wafer instead of SOI if the etching 55 380 has a portion 381 that is flared or tapered proximal to process rates are well characterized. nanochannel 305. Nanochannel 305 is therefore shortened as The nanochannel areas can be patterned on the mask layer a result of portions 341 and 381. using photolithography process. (See FIG. 6(a)), and the mask materials on nanochannel areas are selectively removed Protocol 5 but do not affect underneath silicon. A combination of dry 60 etching, and short time wet etching may be applied for this Hybrid Monolithic-Bonded Capping Layer purpose. A silicon dioxide film (with a well-controlled thick ness) is deposited on the bare silicon area by thermal oxida As a fifth embodiment, a nanochannel structure can be tion. The thickness of the oxidation layer defines the height of fabricated without the use of a CMP process, while utilizing nanochannels, and the mask layer and oxide is stripped. 65 bonding as a non-critical step in the capping layer fabrication. A mask layer suitable for hydroxide (KOH) wet This exemplary microfabrication protocol comprises the fol etching is deposited, such as silicon nitride. A new mask is lowing steps as seen in FIGS. 8A-8P. US 8,480,637 B2 17 18 Referring initially to FIG. 8A, starting with an SOI (silicon Referring now to FIG. 8G, using a photolithography pro on insulator) Substrate wafer 410, a nanochannel spacing cess, outlet microchannels 480 can be patterned and etched layer 420 (with a thickness that is well-controlled, for through optional release layer 421, bonding layer 441, cap example, +5% over the relevant portion of SOI substrate ping material 431, capping layer 430, and optionally through wafer 410) is deposited. The thickness of spacing layer 420 spacing layer 420 into the silicon for additional process lati can be used to define the height of the nanochannels. This tude. spacing layer 420 is a sacrificial layer, and the material will be Referring now to FIG. 8H, a protective capping layer 470 is removed in a Subsequent step, so the silicon Surface immedi deposited over the surface of substrate wafer 410. Wafer 410 ately under it is the “floor of the eventually formed (with layer 421 and bonding layer 441 from wafer 411) is then nanochannels. The spacing material should have a high wet 10 inverted and inlet macrochannels 445 on the back of wafer etch selectivity to all other materials in the nanochannel deliv 410 can be formed by DRIE down to the buried oxide layer ery device. As an example, a thin film of tungsten, germa 450 of wafer 410. nium, or silicon oxide can be used for nanochannel spacing Referring now to FIG. 8I, sacrificial layers (e.g. spacing layer 420. layer 420, capping layer 470, and portions of oxide layer 450) A capping layer 430 is deposited over nanochannel spacing 15 are removed by appropriate processes known in the art. As layer 420. Capping layer 430 will ultimately be the “ceiling shown in FIG. 8I, when spacing layer 420 is removed, of the nanochannels. Silicon nitride, silicon oxide, silicon nanochannels 405 are formed. As illustrated in this embodi carbide, or other material which has a high wet etch selectiv ment, nanochannels 405 are in direct fluid communication ity to the material for spacing layer 420 may be used for with inlet microchannels 440 and outlet microchannels 480. capping layer 430. The nanochannel areas can be patterned on Referring now to FIG.8.J., a top view of the entire wafer 410 spacing layer 420 and capping layer 430 using a photolithog is illustrated. As shown in this view, wafer 410 (prior to raphy process. As shown in FIG. 8B, spacing layer 420 and dicing) comprises several nanochannel delivery devices 400 capping layer 430 on non-nanochannel areas 432 and 433 are (only one of which is identified in the figure). Wafer 410 can etched to or slightly below the silicon surface of silicon wafer be diced to separate the individual nanochannel delivery 410. 25 devices 400 from each other. A detailed view of an individual Referring now to FIG. 8C, additional capping material 431 nanochannel delivery device 400 with exemplary dimensions is deposited, and optionally planarized by CMP to provide a is illustrated in FIG. 8K. In this view, a plurality of inlet flat surface. Inlet microchannels 440 are patterned on the macrochannels 445 are visible on one side of nanochannel mask layer (not shown) using photolithography. The DRIE delivery device 400. This exemplary embodiment of process(es) etchinlet microchannels 440 through the capping 30 nanochannel delivery device 400 is approximately 6.0 mm layer 430 and spacing layer 420 and silicon down to a buried square, and the inlet macrochannels form a generally circular oxidelayer 450 of SOI substrate wafer 410. The mask layer is shape approximately 3.6 mm in diameter. It is understood that removed and additional appropriate Surface layers useful for while wafer 410 of Protocol 5 is illustrated in FIG. 8J, other bonding can be deposited on this surface, as needed. protocols will also yield wafers that comprise multiple Referring now to FIG.8D, on another silicon substrate (e.g. 35 nanochannel delivery devices, and can be diced or separated a capping wafer 411), a layer 421 (comprising, for example, into the individual devices. It is also understood that other silicon nitride or silicon oxide) can be deposited. On top of exemplary embodiments may comprise different dimensions layer 421, a bonding layer 441 is deposited. The material for than those shown in FIG. 8K. In some embodiments, the bonding layer 441 can be chosen so as to adhere well to the wafer 410 may remain whole, effectively forming a material on the Surface of wafer 410 (e.g. capping material 40 nanochannel delivery device with dimensions similar to that 431). The material for bonding layer 441 can also be designed of a silicon wafer, for example, approximately 500 to 750 so that any surface particles can be absorbed into bonding micrometers in thickness and 100, 150, 200, 300, 450, or 675 layer 441 to prevent any delamination between capping wafer mm in diameter. 410 and substrate wafer 411 after bonding. Alternatively, a For example, referring to FIGS. 8L and 8M a nanochannel highly clean process before and during bonding can be used 45 delivery device 500 is shown comprising a body 501 that is without this requirement. Exemplary materials for bonding Substantially planar and has a rectangular shape with a thick layer 441 include polymeric materials, silicon oxide, and ness “T”, a length “L” that is 4 mm and a width “W' that is 3 copper. Before the application of bonding layer 441, option mm. The thickness “T” may be varied, but in certain embodi ally, a material with a very high etch rate, “the release layer” ments is approximately 550-700 um, and is less than either 421, can also be applied with an additional silicon nitride or 50 length L or width W. Length Landwidth W define the primary silicon oxide layer (not shown) on top of this release layer. plane of nanochannel delivery device 500. As shown in the Layer 421 can comprise a material with a high selectivity to figures, body 501 has an inlet surface 502 on one side and an other materials in the nanochannel delivery device. outlet surface 503 on the opposite side. Inlet surface 502 and Referring now to FIG.8E, capping wafer 411 and substrate outlet surface 503 are generally parallel to each other and wafer 410 are then bonded onto each other. In certain embodi 55 parallel to the primary plane of nanochannel delivery device ments, the bonding can be polymer-silicon nitride bond. Such 500. Visible in FIG.8M area plurality of inlet macrochannels as Benzocyclobutene (BCB)-silicon nitride, copper-copper 545 (only one of which is identified in the figure). FIG. 8N thermocompression bond or oxide-to-oxide fusion bond, provides a perspective view of a partial cross-section of each with appropriate pre- and post-bond treatments known nanochannel delivery device 500 taken along line 8N-8N in to those skilled in the art. 60 FIG. 8M. The portion illustrated in FIG. 8N comprises a Referring now to FIG. 8F, the silicon portion of capping single inlet macrochannel 545 and multiple inlet microchan wafer 411 is then removed through a suitable process, e.g. nels 540 and outlet microchannels 580. As shown in FIGS. mechanical thinning, a chemical etch, or a combination of 8L-8N, inlet microchannels 540 and outlet microchannels both. In the case of the optionally added “release layer 421, 580 are formed so that individual inlet and outlet microchan the release layer can be selectively removed to cause separa 65 nels are perpendicular to the primary plane of nanochannel tion of the silicon capping wafer 411 from substrate wafer delivery device 500 (e.g., the length of the microchannels is 410. measured along a line that is perpendicular to the primary US 8,480,637 B2 19 20 plane of the device). In addition, the plurality of inlet micro scribed above). This example is provided for illustration pur channels 540 and outlet microchannels 580 form overlapping poses only and is not intended to limit the scope of the inven arrays so that individual inlet microchannels 580 are distrib tion described herein. uted between individual outlet microchannels 580, and vice Processing begins with a double polished 4" SOI wafer versa. Referring now to FIG. 8As shown in the detailed view (available from Silicon Quest). The wafer comprises a device of FIG. 8O, each nanochannel 505 is in direct fluid commu layer that is 30 um thick, <100> orientation P-type, Boron nication with an inlet microchannel 540 and an outlet micro doped, and a 1-10 Ohm-cm surface resistivity, a buried oxide channel 580. layer that is 0.4 um thick and a handle layer that is 500 um Referring now to FIG. 8P, a detailed section view of a thick, P-type, Boron doped, and 1-10 Ohm-cm surface resis 10 tivity. The wafer was cleaned in a fresh Piranha solution (3:1 section of nanochannel delivery device 500 is illustrated. In 98% sulfuric acid: 30% hydrogen peroxide, over 100 C) for this view, three inlet nanochannels 540 are visible, along with 10 min, and spun dried. A 50 nm pad oxide layer was then a pair of outlet microchannels 580 and a pair of nanochannels thermally grown on the surface. Then a 100 nm low-stress 505. As shown, nanochannel 505 comprises an inlet end 506 nitride was deposited on the pad oxide layer by low-pressure and an outlet end 507. In this embodiment, a first linear axis 15 chemical vapor deposition (LPCVD). The 5 um wide 508 extends between inlet end 506 and inlet Surface 502. Also nanochannel patterns were transferred from the photo mask visible in FIG. 8P, a second linear axis 509 extends between onto the silicon nitride layer by standard photolithography outlet end 507 and outlet Surface 503. using an EVG 620 aligner. The exposed nitride area was Also shown in FIG. 8P, inlet microchannel 540 comprises removed by CF4 RIE. a primary axis 512 and outlet microchannel 580 comprises a After the photoresist was stripped, the pad oxide was primary axis 511. As shown in this embodiment, primary axis cleaned by dipping in 1:10 HF solution. Then the wafer 511 and primary axis 512 are perpendicular to a plane 513 that was placed in a thermal oxide furnace to grow sacrificial is parallel to a substantially planar body 550 of nanochannel oxide. The thickness of this sacrificial oxide determined the delivery device 500. In FIG.8P only a portion of substantially height of nanochannels, i.e. height of planar body 550 is shown. A complete view of substantially 25 nanochannel=0.46*Thickness of Oxide. In this example, a 39 planar body 550 is visible in FIGS. 8L and 8M. nm oxide was grown for 18 nm nanochannels. Then the Referring now to FIG. 9, specific dimensions for an exem nitride and oxide were removed in dilute HF solution. A3 um plary embodiment of a nanochannel delivery device manu thick low temperature oxide (LTO) layer was then deposited factured according to the above protocol are provided. It is on the surface by LPCVD. Then the backside of wafer was 30 protected by 3 um spun-on Futurrex negative photoresist. The understood that these dimensions are illustrative of the spe LTO on front side was removed in a buffered oxide etch cific embodiment shown, and that other embodiments may (BOE) solution, and the wafer was cleaned in piranha solu incorporate different dimensions. tion. Referring now to FIG. 10, a partial cross-section of A 500 nm LTO film was deposited on the wafer using nanochannel delivery device 500 illustrates the diffusion path 35 LPCVD. The 5 umx5 um inlet microchannel patterns were 575 for a molecule passing through nanochannel delivery transferred to the LTO film on the device side of wafer using device 500. It is understood that nanochannel delivery device standard lithography on an EVG 620 aligner, and LTO were 500 may be oriented in any direction during use. As shown in etched using CF4 RIE. Then the 200 umx200 um inlet mac FIG. 10, flow path 105 requires a maximum of two changes in rochannel patterns were transferred onto the backside of the direction between the point where the molecule enters 40 wafer, and RIE was done. nanochannel delivery device 500 and the point at which the After cleaning out the photoresist, deep silicon etching of molecule exits nanochannel delivery device 500. For inlet microchannels was done using an Oerlikon DSE etcher. example, the molecule enters nanochannel delivery device The etching was stopped on the buried oxide layer. The wafer 500 and is initially located within inlet macrochannel 545. was flipped over, and attached onto a handle wafer using The molecule then enters inlet microchannel 540. In the 45 thermal grease (AI Technology). The 190 umx 190 um inlet embodiment shown, flow path 575 turns at a 90 degree angle macrochannels were then etched on the Oerlikon DSE etcher, to the right as the molecule enters the nanochannel 505 that is and stopped on the oxide layer. FIG. 11 shows a SEM image in direct fluid communication with inlet microchannel 540. of deep etched 190 um openings. The wafer was detached After the molecule exits the nanochannel 505, the flow path from the handle wafer, and cleaned. The wafer was dipped in turns again (this time, a 90 degree turn to the left) as it enters 50 BOE for 5 minto open the buried oxide layer, and spun dried. the outlet microchannel 580, which is also in direct fluid Then mask LTO films on both sides of wafer were removed in communication with the nanochannel 505. Therefore, flow HF water solution. path 575 requires a maximum of two changes in direction as A 500 um thick double side polished Pyrex 7740 glass the molecule diffuses through nanochannel delivery device wafer was bonded onto the silicon Substrate as a nanochannel 500. While a molecule may undergo more than two changes 55 cap by anodic bonding using an EVG 520 bonder. The anodic in direction as it passes through nanochannel delivery device binding was performed at 800 volts, and 325°C. for 10 min. 500, it is only required to make two changes in direction. FIG. 12 shows an optical image of the bonded wafer. The bonded wafer pair was adhered on a wafer holder using wax, Example and backlapping was applied to thin the glass down to 30 um, 60 and then CMP polished to a final thickness of 5-10 um (by Protocol 1 Valley Design Corp). FIG. 13 shows an optical image of the front surface after Bonded Capping Layer polishing. The contrast indicates that nanochannels are open. The 5umx5 um outlet microchannels were formed by CF4/ The following example is provided as an illustration of one 65 Ar RIE using Ni film as mask layer. To do so, a copper seed non-limiting embodiment of a method of manufacturing a layer was firstly deposited on the glass surface. The 5umx5 nanochannel delivery device according to Protocol 1 (de um outlet microchannel patterns were transferred to the cop US 8,480,637 B2 21 22 per film using standard lithography on an EVG 620 aligner, slurry combination, under moderate pressure/speed (2-4 psi, and were wet etched. Then Ni was electroplated onto the 30-90 rpm) process. In this same process, the TiN in the patterned copper film. The CF4/Ar RIE was used to etch the non-microchannel area (field) is also completely removed. inlet microchannels into the glass film to reach the silicon Finally, the inlet microchannel process is hardened with a Surface. After stripping the mask layer, the wafer was cleaned, 5 short bake anneal at 150-250C, for about 30 minutes, and the and diced using DAD321 Dicing Saw (Disco). The fabricated surface is cleaned. FIG. 15 presents a top view of the device devices are 6 mmx6 mm overall dimension. There are 161 in after filling with copper. total 190 umx 190 um openings arranged in a 3.6 mm diam A thin silicon nitride (“SiN2) layer of about 50 nm is eter circle. Each such opening is connected to 501 in total 5 deposited by PECVD to cap the copper. The nanochannel umx5um inlet channels, and the inlet channels are connected 10 lines are then exposed in resist (1.3 um) using photolithogra to nanochannel and outlet channels. phy and the silicon nitride (SiN1 as well as SiN2) layers are Example etched, along with the tungsten nanochannel material, with the etch proceeding a few tens of nanometers into the silicon. Protocol 3 15 A thicker, tensile silicon nitride (“SiN3') is then deposited, of a thickness of about 1-1.5 um. The tensile stress of this Monolithically Fabricated Capping Layer layer is chosen so as to make the overall dielectric stack slightly tensile by about 20 MPa. The outlet microchannels The following example is provided as an illustration of one are then exposed on a resist layer (of nominal thickness 2 um) non-limiting embodiment of a method of manufacturing a and a further etch of all silicon nitride layers (SiN1, SiN2, nanochannel delivery device according to Protocol 3 (de SiN3) along with the W nanochannel layer are etched so that scribed above). This example is provided for illustration pur the bottom of the outlet microchannels end in the device poses only and is not intended to limit the scope of the inven silicon. The resist is stripped after this stage. FIG. 16 presents tion described herein. a cross-section of a device at this stage of processing. Processing begins with a double-side polished Silicon On 25 An appropriate protection layer is applied to the Surface— Insulator (SOI) wafer using a 690 um thick base wafer with a Ti/TiN (250/300A), Tungsten (5000A) followed by Phospho top silicon layer thickness of 30 um and a buried oxide thick silicate Glass (PSG) of thickness of 1 um, which can be used ness of 2 um. This wafer is cleaned with a piranha solution as both an HF protectant as well as a surface protectant. The (3:1 98% Sulfuric acid: 30% Hydrogen peroxide, over 100 C) wafer is then turned upside down and a thick resist (10 um) is to remove any organic and metal contamination. A Smooth 30 spun on. Using the front side alignment marks, macrochan (typically <5 Arms), uniform (typically <2% non-unifor nels are exposed on the backside. The macrochannels are mity.) tungsten metal layer is sputtered on this wafer, using a etched all the way through the wafer (about 700 um) using a physical vapor deposition (PVD) process at a temperature of Bosch DRIE process. This process lands on the buried oxide, 100C. The thickness of this tungsten layer is selected to be the which forms an effective etch stop. FIG. 17 presents a cross height of the nanochannel layer, for example 5 nm. 35 section of a test device at this stage of processing. This buried The nanochannel space layer is then covered by a plasma oxide is then removed by a plasma etch. enhanced chemical vapor deposition (PECVD) silicon nitride A series of wet etches are done to remove all the sacrificial (“SiN1) with low stress (380 C, appropriate stoichiometry), materials. A short buffered HF etch, for about 5 minutes, is with a target thickness of 500 nm and a non-uniformity of less done to remove any residual oxide (of the buried oxide), as than 2%. Positive resist is then spun on, with a thickness of 2 40 well as to remove the PSG layer. The wafers are then wet um. The inlet microchannels are exposed in this resist, with etched in an SC-1 solution (hot Ammonium hydroxide— the sizes varying from 1 um to over 5um, as needed. Using hydrogen peroxide mixture) for about 10 minutes to remove this resist, the applied silicon nitride is etched through, along the TiNbarrier at the top surface as well as at the bottom of the with tungsten, using a conventional C4F8 etch chemistry with inlet microchannels. The wafers are Subjected to a piranha appropriate plasma powers, and other reactive and inert 45 etch for about 20 minutes to remove the copper in the inlet gases. microchannels. This is followed by another SC-1 etch to The etch in this process is timed to be deep enough that it remove all the TiN from the sidewalls of the inlet microchan goes through the tungsten layer also, which takes a few min nels. Finally, the Tungsten is removed from the nanochannels utes. Another etch is performed, still using the resist as the by placing the wafers in wafer hydrogen peroxide for 2 hours, mask, to etch a deep via in the silicon that is deep enough to 50 followed by a rinse with DI water. The wafers are then cleaned go into the buried oxide. A 5 dep/5 etch per cycle Bosch etch with Iso-Propyl (IPA) to displace the water with IPA, is used in this step since the etch automatically terminates at, and the wafers are allowed to dry. and is highly selective to, the buried oxide. A small overetch Material Selection of 10-20% of the most critical structure is provided to com Regardless of the protocol used to manufacture the pensate for the non-uniformity of the process. The remaining 55 nanochannel delivery device, the materials used during the resist is then removed using an oxygen plasma and the wafers manufacturing process should be selected to Successfully are additionally cleaned of all polymer residues using an remove sacrificial materials while leaving the non-sacrificial appropriate wet chemistry FIG. 14 presents an example of a materials. As shown in FIG. 18, the selection of a nanochan device at this stage of process. nel “placeholder” (e.g., the sacrificial material used to fill the The next module consists of filling or capping these inlet 60 space of the nanochannel) and nanochannel "ceiling and microchannels. This can be accomplished by plugging the “floor” materials (e.g., the Substrate and capping layers) inlets with copper. A TiNbarrier layer is deposited by sputter, should be coordinated with the selection of a solvent or with a thickness of 300 A. A copper seed layer, with a nominal etchant. Examples of Suitable solvents and etchants that can thickness of about 4000A is deposited through a PVD sputter be used to remove sacrificial materials while leaving the process. A low current (2 A, 10-15 minutes) electroplating 65 substrate and capping layers are shown in FIG. 18. It is process is used to fill or plug the inlet microchannels. The understood that other combinations of materials may be uti excess copper overburden is then polished away using a pad/ lized as well. US 8,480,637 B2 23 24 Post Wafer Processing cone rubber) that permits injection of a therapeutic agent into During post wafer processing, each wafer is attached to a inner volume 750 of cylindrical body 720. In certain embodi tape-ring with an adhesive tape. A UV release tape is pre ments, a therapeutic agent can be injected with a hypodermic ferred since it has better adhesion. Since both surfaces of the needle just prior to implantation of capsule 700. wafer have critical device structures, UV tape is attached to Referring now to FIG. 23, a capsule 800 comprises com both top and bottom surfaces. The wafers are then diced into ponents equivalent to previously-described embodiments. individual die and cleaned. The tapeframe is then exposed to However, this embodiment comprises a cap 825 that covers a UV light source to decrease the adhesion of the tape to the septum 860. Cap 825 may comprise an orifice (not visible in surface. The dice are individually picked and placed into a the perspective view of FIG. 21) configured to guide a needle bare-die holder using an automated pick and place sorter tool. 10 or other device used to penetrate septum 860 and inject a The tape on the top surface of the die is subsequently peeled therapeutic agent into inner volume 850 of cylindrical body off manually. The dice are then individually placed in a final 820. clean container and cleaned with with a final rinse of Referring now to FIG. 24, a capsule 900 comprises a cylin IPA to promote channel drying. A die is attached by epoxy or drical body 922 coupled to a separate end component 935 and other fixing method to a capsule mating Surface. 15 a cap 925. In this embodiment, cylindrical body 922 can be Capsule Configurations replaced with another cylindrical body having a different Referring now to FIGS. 19 and 20, nanochannel delivery length in order to vary the internal volume of capsule 900 (and device 500 may form part of a larger assembly, e.g., a capsule the amount of therapeutic agent that capsule 900 can contain). 600 that may be used to administer drugs or other therapeutic Similar to previous embodiments, end component 935 com agents to a patient. FIG. 19 shows a detailed view of one end prises an end portion 930 configured to receive cap 910. End of capsule 600 in an exploded view, while FIG. 20 illustrates component 935 also comprises a recessed portion 940 con an assembled view of capsule 600. It is understood that in figured to receive nanochannel delivery device 500. other embodiments, nanochannel delivery device 500 may be Referring now to FIGS. 25 and 26, a capsule 1000 com used in other applications where it is desired to precisely prises a disc-shaped body 1020 with a cap 1010 comprising a control the diffusion or passage of Small amounts of any 25 series of exit ports 1015. In this embodiment, disc-shaped Substance. body 1020 comprises a septum 1060 through which a thera In the embodiment shown in FIGS. 19 and 20, capsule 600 peutic agent may be injected. As shown in the exploded view comprises a generally cylindrical body 620 having an end of FIG. 26, supports 1050 can be used to hold nanochannel portion 630 configured to receive a first cap 610 and a second delivery device 500 proximal to exit ports 1015. In this man cap 625. In this embodiment, nanochannel delivery device 30 ner, a therapeutic agent contained within capsule 1000 is 500 is installed in a plane that is perpendicular to the primary forced to pass through nanochannel delivery device 500 axis of capsule 600 (e.g., an axis that is parallel to the length proximal before exiting capsule 1000. of cylindrical body 620 and concentric with cylindrical body In the embodiment shown in FIGS. 27 and 28, a capsule 620). End portion 630 also comprises a recessed portion 640 1100 comprises a rectangular planar surface 1121 and an configured to receive nanochannel delivery device 500. In 35 arched surface 1120. Capsule 1100 also comprises a closed certain embodiments, a glue or other boding agent may be end 1125 and a septum 1160 that can be inserted into an open used to secure nanochannel delivery device 500 in recessed end 1161. In the embodiment shown, septum 1160 covers the portion 640. When assembled, nanochannel delivery device entire open end 1161. In other embodiments, a septum may 500 can be inserted into recessed portion 640, and first cap cover part of an open end, and a cap may cover the remaining 610 may be fitted onto end portion 630. 40 portions. Similar to previously-described embodiments, sep During use, drugs (or any other Substance administered via tum 1160 is self-sealing and can be punctured with a needle to capsule 600) can pass from cylindrical body 620 to nanochan insert atherapeutic agent. Capsule 1100 also comprises a first nel delivery device via an inner volume 650 contained within recessed portion 1140 configured to receive nanochannel cylindrical body 620. After diffusing through nanochannel delivery device 500, and a second recessed portion 1130 delivery device 500 and into first cap 610, the administered 45 configured to receive a cap 1110 comprising exit ports 1115. substances can exit cap 610 via exit ports 615. In exemplary An aperture 1135 extends through recessed portion 1140 into embodiments, the dimensions of exit ports 615 (and other an inner volume 1150 bounded by rectangular planar surface aspects of capsule 610, such as inner volume 650 and cap 610) 1121, arched surface 1120, closed end 1125 and septum 1160. are large enough so that these features do not restrict the In this embodiment, a therapeutic agent can be contained diffusion of the administered substance from capsule 600. As 50 within inner volume 1150 and dispensed through aperture a result, the diffusion of the administered substance can be 1135, nanochannel delivery device 500, and exit ports 1115. more precisely controlled by selecting the dimensions of Referring now to FIG. 29, another embodiment of a cap nanochannel delivery device 500, particularly the dimensions sule 1200 is generally equivalent to capsule 1100, but com of nanochannels 505. Cap 610 may also provide dimensional prises features that accommodate two nanochannel delivery rigidity and protect nanochannel delivery device 500 from 55 devices (not shown). In this embodiment, capsule 1200 com mechanical damage and the incursion of biological tissue prises a rectangular planar Surface 1221, arched surface 1220. structures after implantation. closed end 1225 and septum 1260. Capsule 1200 also com In certain embodiments, inner volume 650 is configured to prises a pair of first recessed portion 1240 each configured to minimize capture points for air bubbles. For example, inner receive nanochannel delivery device (not shown), and a sec volume 650 may comprise radiused corners and surfaces that 60 ond pair of recessed portions 1230 each configured to receive are not angled in a manner (when capsule 600 is installed) a cap with exit ports (not shown). Each recessed portion 1240 which could trap air bubbles. comprises an aperture 1235 that provides fluid communica Referring now to FIGS.21 and 22, capsule 700 is similar to tion between inner volume 1250 and the environment Sur the previously-described capsule 600. However, in this rounding capsule 1200. embodiment capsule 700 is fitted with a septum 760 on the 65 In certain embodiments, inner volume 1250 comprises end of cylindrical body 720 that is distal from end portion separate, internal reservoirs in which each reservoir is in fluid 630. Septum 760 comprises a self-sealing material (e.g., sili communication with a single aperture 1235. The internal US 8,480,637 B2 25 26 reservoirs may be separated by inner walls within aperture 72, 73,74, 75,76, 77,78, 79,80, 81,82, 83, 84,85, 86, 87,88, 1235. In such embodiments, each reservoir may be filled with 89, 90,91, 92,93, 94, 95, 96, 97,98, 99, 100, 101, 102, 103, a separate therapeutic agent. Each nanochannel device can be 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, configured to provide the preferred dosage of each individual 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, therapeutic agent. 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, Referring now to FIG. 30, another embodiment of a cap 140, 141, 142, 143, 144, 145, 146, 147,148, 149, 150, 151, sule 1300 is shown in an installed position so that it partially 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, extends beneath an epidermal surface 1301 of a patient into 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, which capsule 1300 has been inserted. Capsule 1300 com 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186,187, prises multiple covers 1310 with exit ports 1315. Beneath 10 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199 or each cover 1310, a nanochannel delivery device is inserted 200 mm. In other embodiments, the capsule may have a over an aperture that is in fluid communication with an inner length greater than 200 mm. volume of capsule 1300 (similar to the embodiments It is noted that the various embodiments of capsules described in FIGS. 27-29). The inner volume of capsule 1300 described in this disclosure comprise a cross-section that is may be divided into separate compartments so that each 15 nominally constant along the length of the capsule. Such an nanochannel delivery device can be used to administer a optional configuration can facilitate sliding removal from a specific and distinct therapeutic agent. Capsule 1300 also Surgical site within the body without damage to Surrounding comprises an anchor member 1305 configured to serve as a tissue. point at which a suture (not shown) can be attached to capsule In exemplary embodiments a capsule may comprise Suit 1300 when it is installed. Anchor member 1305 may also be able materials such as stainless steel, titanium, polyethere coupled to a string or other device (not shown) used to remove therkeytone, polysulfone, and other plastics and metals. In or retrieve capsule 1300. certain embodiments, a capsule may comprise coating(s) on Referring now to FIG. 31, another embodiment of a cap the interior to provide an optimal environment for a therapeu sule 1400 is shown. This capsule is a minimal covering of the tic Substance and/or coating(s) on the exterior to prevent back and sides of the nanochannel device, such that the “res 25 deleterious tissue encapsulation. In specific embodiments, ervoir' for a contained drug is limited to the volume of the the capsule may comprise color coding to indicate the model macrochannels on the back of the chip (e.g., the nanochannel of the capsule or a particular characteristic (e.g., the thera delivery device), which is about 4.5 mm for the embodiment peutic agent, rate of administering the agent, the capacity of shown in FIG. 8K. This embodiment can be made particularly the capsule, etc.). In certain embodiments, a capsule may Small, for example 2 mmx2 mmx0.5 mm, and is, therefore, 30 comprise a translucent or transparent portion or component especially Suited for implantation with very high (e.g. a cap) to facilitate observation of the quantity of thera drugs into sensitive locations, e.g., glaucoma into peutic agent contained within the capsule. For example, a the inner portion of the eye. translucent or transparent cap covering the nanochannel Exemplary embodiments of the previously-described cap delivery device can allow a person to confirm the capsule is Sules can be sized so that the capsule may be implanted 35 full by orienting the capsule so that the nanochannel delivery Subcutaneously. In specific embodiments, the capsule may device is positioned towards the top of the capsule. A needle have a diameter of 0.5,0.6,0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, (or other loading device) can then penetrate the septum and 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, the therapeutic agent can be injected into the capsule. When 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, liquid appears on the top of the nanochannel delivery device 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 6.0, 7.0, 8.0, 9.0, 10.0, 11.0, 40 (as viewed through the cap), the person filling the capsule will 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0 or 20.0 mm. In have an indication that the capsule is full. other embodiments, the capsule may be greater than 20.0 mm In exemplary embodiments, a capsule may be used to in diameter. administer one or more of the following Substances: adrener In certain embodiments, the capsule may have a thickness gic agent; adrenocortical ; adrenocortical Suppressant; of 0.1, 0.2,0.3, 0.4,0.5,0.6,0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 45 ; alkylating agent; antagonist; amino acid; ana 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, bolic; analeptic; ; ; anorexogenic; anti 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, agent; anti-; anti-allergic; anti-alopecia 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, agent; anti-amebic; anti-anemic; anti-anginal; antiangio 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4., 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, genic, anti-; anti-arthritic; anti-asthmatic; anti-athero 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 50 Sclerotic; antibacterial; ; anticancer; anticholin 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.19.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, ergic; ; ; ; 9.9 or 10.0 mm. In other embodiments, the capsule may have antidiabetic; antidiarrheal; antidiuretic; anti-dyskinetic; anti a thickness greater than 10.0 mm. emetic; anti-epileptic; antifibrinolytic; ; anti-hem In specific embodiments, a capsule may have a width of 1. orrhagic; ; anti-hypercalcemic, anti-hypercho 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 55 lesterolaemic; anti-hyperlipidaemic; anti-hypertensive; anti 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,33, 34,35, 36, 37, hypertriglyceridemic; anti-hypotensive; anti-infective; anti 38,39, 40, 41,42, 43,44, 45,46, 47, 48,49, 50, 51, 52,53,54, inflammatory; anti-ischemic; antimicrobial; antimigraine; 55,56, 57,58, 59, 60, 61, 62,63, 64, 65, 66, 67,68, 69,70, 71, antimitotic; antimycotic; anti-nauseant; anti-neoplastic; anti 72, 73,74, 75,76, 77,78, 79,80, 81,82, 83, 84,85, 86, 87,88, neutropenic; anti-obesity agent; anti-osteoporotic, antipara 89, 90,91, 92,93, 94, 95, 96, 97,98, 99, 100 mm. In other 60 sitic; antiproliferative; ; antiretroviral; anti-re embodiments, the capsule may have a width greater than 100 Sorptives; anti-rheumatic; anti-seborrheic, antisecretory; . ; antisclerotic; ; antitumor, anti In specific embodiments, a capsule may have a length of 1. ulcerative; antiviral; appetite Suppressant, bisphosphonate; 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, blood glucose regulator, , cardiovascular 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,33, 34,35, 36, 37, 65 agent, central agent; contraceptive; cholin 38,39, 40, 41,42, 43,44, 45,46, 47, 48,49, 50, 51, 52,53,54, ergic; concentration aid; ; diagnostic aid; ; 55,56, 57,58, 59, 60, 61, 62,63, 64, 65, 66, 67,68, 69,70, 71, DNA-containing agent, agent; recep US 8,480,637 B2 27 28 toragonist; fertility agent, fibrinolytic; fluorescent agent; free histrelin , Human , oxygen radical Scavenger, gastric acid Supressant, gas hydrochloride, Hydrocodone bitartrate, Hydroxyurea, trointestinal motility effector; ; hydrochloride, Ibandronate, , Imigluc agent; hair growth ; hemostatic; H2 erase, , imiquimod, Sulfate, , antagonist, hormone; hypo cholesterolemic; Interferon beta-1a, Ipratropium, Irbesartan, Irinotecan, Iso hypoglycemic; hypolipidemic; hypotensive; imaging agent; niazid, Isosorbide moninitrate, ixabepilone, , keto immunizing agent; immunomodulator; immunostimulant; conazole, , Lactobionate, Lamivudine, Lamivu immunosuppressant, interleukin, keratolytic; LHRHagonist; dine, , lanreotide acetate, Lansoprazole, mood regulator, mucolytic, mydriatic; nasal ; lapatinib, , , Letrozole, Leuprolide, neuromuscular blocking agent; neuroprotective; NMDA 10 Levalbuterol, hydrochloride, , antagonist; non-hormonal sterol derivative; agent; dihydrochloride, levodopa, , parasympathomimetic agent, , platelet , , levothyroxine , activating factor antagonist, platelet aggregation inhibitor, , , Dimesylate, Lisi platinum-containing agent, psychotropic; radioactive agent; nopril, Lispro , Lopinavir, , , rafantagonist, RNA-containing agent, Scabicide; Sclerosing 15 Losartan potassium, maraviroc, Marinol, hydro agent; ; sedative-; selective A1 chloride, , , , , antagonist; selective modulator, , Metformin Hydrochloride, , methoxy antagonist; serotonin inhibitor, serotonin receptorantagonist; polyethylene glycol-epoetin beta, , Meth steroid; stimulant; thrombic agent; thyroid hormone; thyroid ylphenidate hydrochloride, , Metoprolol tartrate, inhibitor, thyromimetic; tranquilizer, vasoconstrictor, , Metronidazole, miglitol, , vasodilator, wound healing agent; oxidase inhibitor; Minocycline hydrochloride, mirtazepine, , and the like; Abacavir, Abacavir Sulfate, abatacept, Acarbose, , , Montelukast Sodium, , Acetaminophen, Aciclovir, Adalimumab, Adapalene, Alen , Mycophenolate mofetil, , dronate, Alendronate Sodium, , alliskiren, allopu Sodium, natalizumab, Neostigmine , , Nicoti rinol, , , Aminocaproic acid, Amitrip 25 namide, , , nilotinib hydrochloride tyline hydrochloride, , amlodipine besylate, monohydrate, , hydrochloride, , amoxicilline, , , Arip , , Olanzepine, Olmesartan, olmesartan iprazole, , Atazanavir, , , medoxomil, hydrochloride, , , atorvastatin, Sulfate, AZelas Omega-3 acid ethyl esters, , , Orl tine, azithromycin, Balsalazide, Benazepril, bendamustine 30 istat, Oseltamivir, Oxaliplatin, , Oxybytynin hydrochloride, Benzepril hydrochloride, bevacizumab, chloride, oxycodone hydrochloride, , Palivizumab, , , , Bisoprolol fumarate, Pantoprazole, , , paroxetine hydro , Botulin toxin, , Buformin, Buprenor chloride, Pegylated interferon alfa-2a, , Penicil phine, , bupropion hydrobromide, Bupropion lamine, V potassium, Phenformin, Phenyloin Hydrochloride, , Calcipotriol, calcitriol, cande 35 sodium, Pioglitazone, , Potassium chloride, Sartan cilexetil, Capecitabine, , , cariso , , Pravastatin sodium, prodol, , , , , fumerate, , Primaquine phosphate, , , , , cephalaxin, , , Promethazine hydrochloride, Certolizumab Pegol, , Cetrizine hydrochloride, Proponolol hydrochloride, Propoxyphene hydrochloride, Cetuximab, hydrochloride, Chlorphe 40 , Pseudophedrine hydrochloride, Pyri niramine maleate, , , , Cina dostigmine bromide, Pyridoxine hydrochloride, Quetiapine, calcet, , hydrobromide, Clarithro quetiapine fumarate, Quinapril hydrochloride, Rabeprazole, mycin, , Clindamycin, clindamycin , raltegravir, Ramipril, , Ranitidine hydrochloride, hydrochloride, hydrochloride, Recombinant factor VIII, retapamulin, hydrochloride, , Clopidogrel bisulfate, Cloxacil 45 , Risedronate, Risedronate sodium, , lin Sodium, Co-Amoxiclav, phosphate, , , rituximab, Rivastigmine, rivastigmine tartrate, , hydrochloride, Cyclophos , , rosiglitaZone, RosiglitaZone male phamide, Cyclosporine, darbepoetin alfa, , ate, , Rotavirus Vaccine, , . DCRM 197 protein, , desloratidine, Desmo Salbutamol sulfate, , sapropterin dihydrochloride, pressin Sulfate, , , 50 , sertraline hydrochloride, Sevelamer, , , citrate, , , sildenafil citrate, , Simvastatin, Sita , , DL-, Doc gliptin, Sodium , , Somatostatin, Soma etaxel, , , Dorzolamide, , tropin, Stavudine, Sulfomethoxazole, , doxazosin mesylate, doxycydine, , , Sumatriptan Succinate, , , cit Dutasteride, eculizumab, , Emtricitabine, Enala 55 rate, , tamsulosin hydrochloride, , pril, enalapril maleate, , Eprosartan, Erlo , , , , tinib. , Erythropoetin, , esomepra Tenofovir, Hydrochloride, , Teri Zole, , Estrogen, , etanercept, paratide, , hydrochloride, Thalido Ethembutol hydrochloride, , ethynl estradiol, mide, thymopentin, meleate, Tiotropium, tipranavir, , , etravirine, , , 60 , tolterodine tartrate, , topotecan, Tra EZetimibe, Factor VII, , Famotidine, , madol, Tramodol hydrochloride, trastuzumab, Fenofibrate, , Fentanyl citrate, Ferrous sulfate, Fex hydrochloride, , Valaciclovir, Valacyclovir ofenadine, hydrochloride, Filgrastim, Finas hydrochloride, Valproate semisodium, Valsartan, Vancomy teride, , hydrochloride, , cin, . , , Venlafaxine hydro , folic acid, Follitropin alfa, Follitropin beta, For 65 chloride, Hydrochloride, vildagliptin, Voglibose, moterol, sodium, , Gabapentin, Gem , Wafarin sodium acetylsalicylic acid, , citabine, glargine insulin, Glatiramer, glimepride, , Zidovudine, , Zoledronate, , or phar US 8,480,637 B2 29 30 maceutically acceptable salts thereof; 16- fluoroestra , Aprindine Hydrochloride, aprosulate Sodium, diol, 17-alpha dihydroequilenin, 17-alpha estradiol, 17-beta Aprotinin, Maleate, , apurinic acid, apu estradiol, 17-hydroxyprogesterone, 1-dodecpyrrolidinone, rinic acid, , Aranotin, Arbaprostil, arbekicin, arbi 22-oxacalcitriol, 3-isobutyl-gammabutyric acid, 6-fluorour dol, Hydrochloride, Arclofenin, Ardeparin Sodeoxycholic acid, 7-methoxytacrine, Abacavir, Abacavir Sodium, , Arginine, Argipressin Tannate, Aril Sulfate, Abamectin, , abatacept, , abirater done, , armodafinil, , Arpinocid, Arte one, Ablukast, Ablukast Sodium, Acadesine, , flene, Artilide Fumarate, , aspalatone, Asparagi Acarbose, , Acecamide Hydrochloride, Aceclid nase, , Aspartocin, asperfuran, , ine, aceclofenae, Acedapsone, Acedapsone, aspoxicillin, Asprelin, , Astromicin Sulfate, asu Aluminum, Acemannan, Acetaminophen, , 10 lacrine, , Atazanavir, Atenolol, , Ati , , acetomepregenol, pamezole, Maleate, Atolide, Atomoxetine, atorvas Maleate, Acetosulfone Sodium, Acetylcho tatin, Atorvastatin Calcium, Atosiban, , atpenin line Chloride, , acetyl-L-, acetyl B, Atracurium Besylate, , atrinositol, Atropine, methadol, Aciclovir, Acifran, , acitemate, Acitretin, Atropine Sulfate, Auranofin, aureobasidin A, Aurothioglu , Aclarubicin, aclatonium, Acodazole Hydrochlo 15 cose, Avilamycin, Avoparcin, Avridine, AXid, axinastatin 1, ride, aconiazide, Acrisorcin, , Acronine, Actiso axinastatin 2, axinastatin 3, AZabon, AZacitidinie, AZaclo mide, Actodigin, Acyclovir, acylfulvene, Hydro rzine Hydrochloride, AZaconazole, azadirachtine, chloride, , Adalimumab, Adapalene, adatanserin, Dihydrochloride, Azaloxan Fumarate, AZanator Maleate, adecypenol, adecypenol, Adefovir, adelmidrol, ademetion AZanidazole, , AZaribine, AZaserine, , ine, Adenosine, , Adipheinine Hydrochloride, Maleate, , AZathioprine Sodium, aza adiposin, Adozelesin, , Adrenalone, AiclometaSone toxin, azatyrosine, , , , Dipropionate, airbutamine, alacepril, Alamecin, , , AZetepa, , Azithromycin, , , alaptide, , albolabrin, Albuterol, AZolimine, AZosemide, AZotomycin, , Alclofenae, Alcloxa, aldecalmycin, Aldesleukin, Aldioxa, AZumolene Sodium, Hydrochloride, baccatin Aletamine Hydrochloride, Alendronate, Alendronate 25 III, , , bacoside A, bacoside B, bactobola Sodium, alendronic acid, , Alentemol Hydrobro mine, balanol, balaZipone, balhimycin, balofloxacin, bal mide, Aleuronium Chloride, Alexidine, alfacalcidol, Alfenta salazide, Bambermycins, , Sulfate, nil Hydrochloride, alfuzosin, Acetonide, algluc Hydrochloride, Bamidazole, baohuoside 1, Bar erase, , alinastine, Alipamide, alliskiren, Allantoin, mastine, , Basic, Basifungin, Hydro , , Alonimid, , Alosetron 30 chloride, batebulast, Maleate, Batimastat, beau Hydrochloride. Alovudine, Alpertine, alpha-idosone, Alpi vericin, Becanthone Hydrochloride, becaplermin, beclicona dem, , Hydrochloride, Alprenoxime Zole. Beclomethasone Dipropionate, , Beinser Hydrochloride, Alprostadil, Alrestatin Sodium, azide, Belfosdil, Belladonna, Beloxamide, , Tartrate. . Althiazide, Altretamine, altromycin B, Bemitradine, Bemoradan, Benapryzine Hydrochloride, Alverinc Citrate, alvimopan, Alvircept Sudotox, 35 Benazepril, Benazepril Hydrochloride, Benazeprilat, Benda Acetate, Hydrochloride, ambamustine, Ambo calol Mesylate, bendamustine hydrochloride, , mycin, ambrisentan, Ambruticin, Ambuphylline, Ambuside, Bendroflumethiazide, benflumetol, , , , , Amdinocillin, Amdinocillin Piv , Benoxaprofen, Benoximate Hydrochloride, oxil, Hydrochloride, , Ameltolide, , , Bentiromide, Benurestat, BenZbro , Ametantrone Acetate, , 40 marone, Benzepril hydrochloride, Benzethonium Chloride, amfebutamone, Sodium, Amfiutizole, Amicycline, Benzetimide Hydrochloride, Benzilonium Bromide, Benzin Mesylate, amidox, Amifloxacin, amifostine, dopyrine Hydrochloride, , , ben Amilcacin, Hydrochloride, Aminacrine Hydro Zochlorins, Hydrochloride, Benzodepa, ben chloride, Aminobenzoate Potassium, Aminobenzoate Zoidazoxan, , Benzoyl Peroxide, Sodium, Aminocaproic Acid, , Amino 45 benzoylstaurosporine, , Benzthiazide, benz hippurate Sodium, aminolevulinic acid, . A tropine, Benztropine Mesylate, Hydrochlo minorex, Aminosalicylate Sodium, Aminosalicylic acid, ride, Benzylpenicilloyl Polylysine, , Bepridil Hydro , Amiprilose Hydrochloride, Amiquinsin Hydro chloride, Beractant, , , berlafenone, chloride, , , Hydrochlo bertosamil, Berythromycin, besipirdine, betaalethine, ride, , amlodipine, amlodipine besylate. Amobar 50 betaclamycin B. , betamipron, . bital Sodium, , Amodiaquine Hydrochloride, Betaxolol Hydrochloride, Chloride, Bethani , , Amoxicillin, Amphecloral, dine Sulfate, betulinic acid, bevacizumab, , Bevan Amphetamine, Amphetamine Sulfate, Amphomycin, tolol Hydrochloride, , Bialamicol Hydrochloride, Amphoterin B, , ampiroxieam, AmpyZine Sulfate, , Bicalutamide, Biciifadine Hydrochloride, Biclodil Amquinate, , amrubicin, Amsacrine, Amylase, 55 Hydrochloride, Bidisomide, , , , amythiamicin, Acetate, , , Bimatoprost, bimithil, Bindarit, Biniramycin, Anakinra, ananain, anaritide, Anaritide Acetate, Anastrozole, , bioxalomycin, Bipenamol Hydrochloride, Anazolene Sodium, , andrographolide, Androstenedi , Biphenamine Hydrochloride, biriperone, bisant one, Angiotensin Amide, Anidoxime, , rene, bisaramil, bisaziridinylspermine, bis-benzimidZole A, Hydrochloride, , Anirolac, Anisotropine Methyl 60 bis- B, bisnafide, Bisobrin Lactate, Bisoprolol, bromide, , , , antagonist D. Bisoprolol fumarate, Bispyrithione Magsulfex, bistramide D, antagonist G, antarelix, Phosphate, Anthelmycin, bistramide K, bistratene A, Bithionolate Sodium, Anthralin, Anthramyciantiandrogen, , antine Mesylate, , Bizelesin, Bleomycin Sulfate, bol oplaston, Antipyrine, antisense oligonucleotides, apadoline, dine, Dipropionate, , apafant, Apalcillin Sodium, apaxifylline, ApaZone, aphidi 65 Undecylenate, , , , Bosentan, colin glycinate, Apixifylline, Hydrochloride, Botulin toxin, Boxidine, brefeldin, breflate, Brequinar , Apraclonidine Hydrochloride, Apramycin, Sodium, , Tosylate, Hydro US 8,480,637 B2 31 32 chloride, , Brinolase, Brocresine, Brocrinat, Bro Hydrochloride, Chloropropamide, Chloroquine, chloroqui foxine, Maleate, , Bromchlo noxaline , Chlorothiazide, , renone, Bromelain, , Brominidione, , Chloroxylenol, Chlorpheniramine Maleate, , Bromodiphenhydramine Hydrochloride, Chlorphenesin , Chlorpheniramine maleate, Chlo Bromoxanide, , Bromperidol Decanoate, Bro rpromazine, Chlorpromazine hydrochloride, Chlorpropam mpheniramine Maleate, Broperamole, Bropirimine, Broti ide, , Chlortetracycline Bisulfate, Chlortha Zolam, Bucamide Maleate, , Hydrochlo lidone, , Cholestyramine Resin, Chromonar ride, Bucromar one, Budesonide, , budotitane, Hydrochloride, cibenzoline, cicaprost, Hydro Buformin, , Bunaprolast, , Bunolol chloride, , ciclesonide, cicletanine, , Hydrochloride, , Hydrochloride, 10 Cicloprofen, , Cidofovir, Hydrochlo Buprenorphine, Buprenorphine Hydrochloride, Bupropion, ride, Cifenline, , Hydrochloride, bupropion hydrobromide, Bupropion Hydrochloride, Bura , Cilastatin, Cilastatin Sodium, CilaZapril, cilnid mate, Buserelin Acetate, Hydrochloride, Busul ipine, Mesylate, cilobradine, , cilosta fan, , Butacetin, Hydrochloride, Zol, , Cimetidine, , Cinacal , , Citrate. , 15 cet, Cinalukast, Hydrochloride, Butaprost, Butedronate Tetrasodium, . Buterizine, Maleate, Cinflumide, , , , buthioninc sulfoximine, Butikacin, Butilfenin, Butirosin Sul , , , Cinperene, Cinro fate. Butixirate, propionate, Nitrate, mide, Cintazone, Cintriamide, , Cipamfylline, Butonate. Butopamine. Butoprozine Hydrochloride. Butor Succinate, , , Ciprof phanol, Butoxamine Hydrochloride, Hydrochlo loxacin, ciprostene, , Cirolemycin, Cisplatin, ride, Cabergoline, Cactinomycin, Cadexomer , Caf , , Cisconazole, cis-porphyrin, feine, calanolide A, Calcifediol, Calcipotriene, calcipotriol, cistinexine, citalopram, citalopram hydrobromide, Citena , Calcitriol, Calcium Undecylenate, calphostin C, mide, , citreamicin alpha, cladribine, Clamoxyquin , Cambendazole, Cammonam Sodium, camon Hydrochloride, , clausenamide, Clavulanate agrel, canary pox IL-2, candesartan, candesartan cilexetil, 25 Potassium, , Clazolimine, , , , , candoXatrilat, Caniglibose, Can Maleate, , , renoate Potassium, , capecitabine, Capobenate Clindamycin, clindamycin hydrochloride, , ClioX Sodium, Capobenic Acid, Capreomycin Sulfate, capromab, anide, Cliprofen, , Propionate, Clobeta , Captopril, Capuride, Carbocysteine, Caracemide, sone Butyrate, Acetate, Clodanolene, Clodazon , Carbadox, , Carbamide Peroxide, 30 Hydrochloride, clodronic acid, Clofazimine, , Clo Carbantel Lauryl Sulfate, Carbaspirin Calcium, Carbazeran, filium Phosphate, Cloge stone Acetate, Clomacran Phos carbazomycin C, Potassium, phate, Acetate, Clometherone, , Sodium, Carbetimer, carbetocin, Carbidopa, Carbidopa clomifeneanalogues, , Clomiphene, Clomi Levodopa, Maleate, Carbiphene Hydrochlo pramine Hydrochloride, , Clonidine, Clonidine ride, Carbocloral, Carbol-Fuchsin, Carboplatin, , 35 hydrochloride, Clonitrate, Clonixeril, , Clopamide, carbovir, carboxamide-amino-triaZo-le, carboxyamidotriaz , Cloperidone Hydrochloride, clopidogrel, Clo ole, carboxymethylated beta-1,3-glucan, Hydro pidogrel bisulfate, , Clopipazan Mesylate, Clo chloride, CaRest M3, Citrate, , Car pirac, , Sodium, Dipo mantadine, Carmustine, CARN 700, Carnidazole, tassium, Clorethate, Clorexolone, Cloroperone , carperitide, Carphenazine Maleate, , 40 Hydrochloride, Clorprenaline Hydrochloride, Clorsulon, Carsatirin Succinate, , , Carteolol Hydro Clortemine Hydrochloride, Closantel, Closiramine Acetu chloride, Carubicin Hydrochloride, carvedilol, carvotroline, rate, Clothiapine, Clothixamide Maleate Propi Carvotroline Hydrochloride, carzelesin, Caspofungin, onate, , BenZathine, Cloxacillin castanospermine, caurumonam, cebaracetam, cecropin B, Sodium, Cloxyquin, , Co-Amoxiclav, , Cedefingol, , , , Cefaparole, 45 Coccidioidin, Codeine, Codeine phosphate, , , Sodium, , piv , Colesevelam, colestimide, Hydro oxil, cefdaloxime pentexiltosilate, Cefdinir, piv chloride, Colestolone, , Colfosceril Palmitate, oxil, , , Cefetecol, , , Colistimethate Sodium, Sulfate, collismycin A, col Cefinenoxime Hydrochloride, Cefinetazole, cefiminlox, cefo lismycin B, Mesylate, combretastatin A4, com dizime, Sodium, CefoperaZone, Cefoperazone 50 plestatin, conagenin, Conorphone Hydrochloride, contignas Sodium, , , Sodium, terol, contortrostatin, Cormethasone Acetate, , cefotiam, , , , Ovine Tnflutate, Corticotropin, Acetate, Cortiva Ce?piramide, , proxetil, cefprozil, Zol, Cortodoxone, cosalane, costatolide, Cosyntropin, coti , , , , , nine, Coumadin, Coumermycin, crambescidin, Crilvastatin, Sodium, ceftriaxooe, Cefuroxime, celastrol, 55 crisinatol, Cromitrile Sodium, Cromolyn Sodium, Crotami Celecoxib, celikalim, , cepacidine A, Cephacetrile ton, cryptophycin, cucumariosid Cuprimyxin, curacin A, Sodium, Cephalexin, Cephaloglycin, , Cepha curdlan Sulfate, curiosin, Cyclacillin, , cycla lothin Sodium, Cephapirin Sodium, Cephradine, cer Zosin, Cyclindole, Cycliramine Maleate, , iclamine, , Ceruletide, Ceronapril, Certolizumab Cyclobendazole, cyclobenzaprine, cyclobenzaprine hydro Pegol, certoparin sodium, Cetaben Sodium, Cetalkonium 60 chloride, cyclobut A, cyclobut G, cyclocapron, Cycloguanil Chloride, Hydrochloride, CethuperaZone, Pamoate, Cycloheximide, cyclopentanthraquinones, Cyclo , cetirizine, Cetophenicol, Cetraxate Hydrochloride, penthiazide, Hydrochloride, Cyclophenazine Cetrizine hydrochloride, , Cetuximab, Cetylpyri Hydrochloride, , cycloplatam, Cyclopro dinium Chloride, Chenodiol, Chlophedianol Hydrochloride, pane, , cyclosin, Cyclosporine, cyclothialidine, Betaine, , , Chlordan 65 , cyclothiazomycin, Cyheptamide, cypemycin, toin, , Gluconate, chlorins, Cyponamine Hydrochloride, , Acetate, chloroorienticin A, Hydrochloride, Cyprolidol Hydrochloride, , US 8,480,637 B2 33 34 Cyproximide, Cysteamine, Hydrochloride, Cystine, mesylate, doxycydine, Drospirenone, Duloxetine, Dutast Cytarabine, Cytarabine Hydrochloride, cytarabine ocfosfate, eride, , ebiratide, , ebselen, ecabapide, cytochalasin B, cytostatin, Dacarbazine, dacliximab, dac ecabet, , ecdlisteron, echicetin, echistatin, timicin, Dactinomycin, , Tosylate, dalfo Echothiophate Iodide, Maleate, EclaZolast, eco pristin, , Daltroban, Dalvastatin, danap mustine, , ecteinascidin 722, eculizumab, edara aroid, , , daphlnodorin A, , vone, Edatrexate, edelfosine, Edifolone Acetate, edobaco dapitant, Hydrochloride, , , mab, Edoxudine, edrecolomab, Edrophonium Chloride, darbepoetin alfa, DarglitaZone Sodium, darifenacin, darlucin edroxyprogesteone Acetate, Efavirenz, efegatran, eflorni A, , darsidomine, Daunorubicin Hydrochloride, thine, , egualcen, Elantrine, eleatonin, elemene, Dazadrol Maleate, Dazepinil Hydrochloride, Dazmegrel, 10 , elgodipine, , Elsamitrucin, eltenae, Fumarate, Hydrochloride, DCRM 197 Elucaine, emailcalim, , Hydrochloride, protein, Debrisoquin Sulfate, Decitabine, deferiprone, emiglitate, Emilium Tosylate, emitefur, emoctakin, Emtricit , Dehydrocholic Acid, dehydrodidemnin B, Dehy abine, Hydrochloride, Enailciren, enalapril, enala droepiandrosterone, delapril, Delapril Hydrochloride, pril maleate, enaZadrem, Encyprate, Endralazine Mesylate, Mesylate, deleduanine, delfaprazine, Delmadi 15 Endrysone, , englitaZone, Enilconazole, Eniso none Acetate, delmopinol, delphinidin, Demecarium Bro prost, Enlimomab, Enloplatin, Enofelast, Enolicam Sodium, mide, Demeclocycline, Demecycline, , Deno , enoxacin, enoxaparin Sodium, Enoxaparin fungin, deoxypyridinoline, Depakote, , Deprostil, Sodium, , Enpiroline Phosphate, , depsidomycin, , , Desciclovir, Enpromate, , enterostatin, Enviradene, Acetonide, Desfurane, Hydrochlo Enviroxime, , , , Epinephrine, ride, desirudin, Deslanoside, Desloratadine, deslorelin, des Epinephryl Borate, Epipropidine, Epirizole, epirubicin, mopressin, Desmopressin Sulfate, , , Epitetracycline Hydrochloride, Epithiazide, Epoetin Alfa, DeSoximetaSone, desoxoamiodarone, Desoxy-corticoster Epoetin Beta, Epoprostenol, Epoprostenol Sodium, one Acetate, detajmium bitartrate, Hydrochloride, epoxymexrenone, epristeride, Eprosartan, eptastigmine, Detirelix Acetate, , Dexamethasone, Dexamisole, 25 , , Erbulozole, , Mesy Maleate, Male lates, Ergonovine Maleate, Tartrate, Erlotinib, ate, Dexclamol Hydrochloride, , Dexfenflu , Ersofermin, erythritol, Erythrity1 Tetranitrate, ramine Hydrochloride, dexifosfamide, Deximafen, dexketo Erythromycin, Erythropoetin, Escitalopram, Hydro profen, , , Dexormaplatin, chloride, esomeprazole, Esorubicin Hydrochloride, Espro Hydrochloride, Dexpanthenol, Dexpemedolac, 30 quin Hydrochloride, , Estradiol, , Dexpropranolol Hydrochloride, Dexrazoxane, dexsotalol, Hydrobromide, , , Estrogen, dextrin 2-sulphate, , , , , , Eszopiclone, Hydrochloride, Sodium, dex Hydrochloride, etanercept, Etanidazole, etanterol, Etarotene, Verapamil, DeZaguanine, dezinamide, , Hydrochloride, , ethacizin, Ethacrynate Hydrochloride, Diamocaine Cyclamate, Diapamide, Diatri 35 Sodium, Ethacrynic Acid, Ethambutol Hydrochloride, Zoate Meglumine, Diatrizoic Acid, Diaveridine, , Ethamivan, Ethanolamine Oleate, Ethehlorvynol, Ethembu Diaziquone, , Hydrochloride, Diben tol hydrochloride, Ethinyl estradiol, Ethiodized Oil, Ethiona Zothiophene, Dibucaine, Dichliorvos, , mide, Ethonam Nitrate, Ethopropazine Hydrochloride, Etho Dichlorphenamide, , Diclofenac, Diclofenac Suximide, Ethosuximide, , Ethoxazene Sodium, , dicranin, Dicumarol, Dicyclomine 40 Hydrochloride, Ethybenztropine, Ethyl Chloride, Ethyl Hydrochloride, Didanosine, didemnin B, didox, , , , Ethyndiol, , ethynlestra , Diethylcarbamazine Citrate, diethylhomosper diol, Ethynodiol Diacetate, Etibendazole, , Etidr mine, diethylnorspermine, Diethylpropion Hydrochloride, onate Disodium, Etidronic Acid, Etifenin, Etintidine Hydro . Difenoximide Hydrochloride. , chloride, , , , Etoformin Diacetate. Hydrochloride. Difluanine 45 Hydrochloride, , Etonogestrel, Hydrochloride. . Diflumidone Sodium, Hydrochloride, Etoposide, Etoprine, etoricoxib, , Difluprednate, Diftalone, Digitalis, , Hydrochloride, Etozolin, etrabamine, etravirine, Etretinate, , Dihexy verine Hydrochloride, , dihy Etryptamine Acetate, Eucatropine Hydrochloride, Eugenol, dro-5-azacytidine, Bitartrate, Dihydroer Euprocin Hydrochloride, eveninomicin, Exametazime, gotamine Mesylate, Dihydroestosterone, Dihydrostreptomy 50 examorelin, Hydrochloride, , cin Sulfate, Dihydrotachysterol, Dilantin, Dilevalol Exenatide, EZetimibe, EZetimibe, Factor VII, , fae Hydrochloride, Hydrochloride, Dimefadane, rieflungin, , Famotidine, Fampridine, , Dimefline Hydrochloride, , , Fantridone Hydrochloride, , fasidotril, , Dimethadione, Dimethindene Maleate, , fazarabine, , , felbamate, , , dimethylhomospermine, dimethylpros 55 , Fely pressin, Fenalamide, Fenamole, Fenbenda taglandin A1, , Dimoxamine Hydrochloride, Zole, , Fencibutirol, , , Fen Dinoprost, Dinoprostone, Dioxadrol Hydrochloride, dioxa clorac, Fendosal, , Hydrochloride, mycin, diphenhydramine, Diphenhydramine Citrate, Hydrochloride, Fengabine, Fenimide, Fen Diphenidol, Hydrochloride, diphenylspiro isorex, Hydrochloride, , mustine, Dipivefin Hydrochloride, Dipivefrin, diplien 60 Fenobam, Fenoctimine Sulfate, Fenofibrate, , cyprone, , dipropylnorspermine, Dipyridamole, , , Fenpipalone, Fenprinast Hydrochlo Dipyrithione, Dipyrone, dirithromycin, discodermolide, Dis ride, Fenprostalene, Fenguizone, fenretinide, , fen obutamide, Disofenin, , Disoxaril, disulfuram, tanyl, Fentanyl Citrate, , Fenticlor, , Ditekiren, Divalproex Sodium, Maleate, DL-me Fenyripol Hydrochloride, fepradinol, ferpifosate sodium, fer thionine, , docarpamine, Docebenone, Doc 65 ristene, ferrixan, Ferrous Sulfate, Ferumoxides, ferumoxsil, etaxel, Doconazole, docosanol, dolfetilide, , Done Fetoxylate Hydrochloride, Fexofenadine, fexofenadine pezil, doripenem, Dorzolamide, Doxazosin, doxazosin hydrochloride, Fumarate, Fiacitabine, Fialuri US 8,480,637 B2 35 36 dine, fibmoxef, Fibrinogen, Filgrastim, Filipin, Finasteride, mide, hexamethylene bisacetamide, Hexedine, , fiorfenicol, fiorifenine, fiosatidil, fiumecinol, fiumarizine, Sulfate, Hexylresorcinol, Histamine Phos fiuparoxan, fiupirtine, fiurithromycin, fiutrimazole, fiuvasta phate. . Histoplasmin, Histrelin, histrelin acetate, tin, fiuvoxamine, Flavodilol Maleate, flavopiridol, Hydrobromide, Hoquizil Hydrochloride, Hydrochloride, Flazalone, flecamide, flerobuterol, Fleroxa Human chorionic , Human growth hormone, cin, , Sulfate, , flezelastine, Hycanthone, Hydralazine Hydrochloride, Hydralazine Polis flobufen, , Flordipine, , Floxacillin, tirex, , Hydrocodone Bitartrate, Hydro Floxuridine, fluasterone, , Flubanilate Hydrochlo cortisone, Hydroflumethiazide, Hydrochlo ride, Flubendazole, , Flucloronide, Fluconazole, ride, Hydroxyamphetamine Hydrobromide, , Fludalanine, Fludarabine Phosphate, Fludazo 10 Hydroxychloroquine Sulfate, , Hydrox nium Chloride, Fludeoxyglucose, , yprogesterone Caproate, Hydroxyurea, Hydroxy Zine Hydro Acetate, , Flufenisal, , Flume chloride, Hymecromone, , , Ibafloxa quine, Flumeridone, Flumethasone, Flumetramide, Flumeza cin, Ibandronate, , Ibopam, , Ibufenac, pine, , , , Flunidazole, , Fumarate, Acetate, Ichtham , , , fluocalcitriol, Fluoci 15 mol, Icotidine, idarubicin, , Idoxuridine, idraman nolone Acetonide, , Butyl, Fluocor tone, , Ifosfamide, Ilepeimide, illimaquinone, ilmo tolone, Fluorescein, fluorodaunorunicin hydrochloride, Fluo fosin, illomastat, Ilonidap, illoperidone, , Imafen rodopa, , Fluorouracil, Hydrochloride, Imatinib, Imazodan Hydrochloride, imi Hydrochloride, Fluoxetine, Fluoxetine hydrochloride, Flu dapril, , imidazoacridone. Imidecyl Iodine, Imi , Fluperamide, Acetate, Fluphena docarb Hydrochloride, Imidoline Hydrochloride, Imidurea, Zine Decanoate, , FluproduaZone, Flupros Imiglucerase, Hydrochloride. Imipenem, Imi tenol Sodium, FluquaZone, Fluradoline Hydrochloride, pramine Hydrochloride, imiquimod, Hydro Flurandrenolide, Hydrochloride, , chloride, Indacrinone, Indapamide, Indecamide Hydrochlo Fluretofen, Fluorocitabine, Fluorofamide, Fluorogestone ride, Hydrochloride, Indigotindisulfonate Acetate, Fluorothyl, Fluoroxene, Fluspiperone, , 25 Sodium, indinavir, Indinavir Sulfate, Indocyanine Green, Fluticasone, , Flutroline, Fluvastatin, Indolapril Hydrochloride, Indolidan, , Fluvastatin Sodium, Fluzinamide, Folic Acid, Follicle regu Indomethacin Sodium, , , latory protein, Folliculostatin, Follitropin alfa, Follitropin Hydrochloride, Indoxole, Indriline Hydrochloride, inflix beta, Fomepizole, Fonazine Mesylate, forasartan, forfen imab, , , inolimomab, Niaci imex, forfenirmex, , , , 30 nate, Insulin, Interferon beta-1a, Intrazole, Fosarilate, , Foscarnet Sodium, , Fos Hydrochloride, iobenguane, Iobenzamic Acid, iobitridol, fonet Sodium, fosinopril, Fosinopril sodium, Fosinoprilat, Iodine, iodoamiloride, iododoxorubicin, iofratol, iomeprol, fosphenyloin, Fosquidone, , fostriecin, fotemustine, iopentol, iopromide, iopyrol, iotriside, ioxilan, ipazilide, Fuchsin, Fumoxicillin, Fungimycin, Furaprofen, Furazoli ipenoxazone, ipidacrine, Ipodate Calcium, ipomeanol, Ipra done. Furazolium Chloride. Furegrelate Sodium, Furobufen, 35 tropium, , ipriflavone, prindole, Ipro Furodazole, , Fusidate Sodium, Fusidic Acid, fenin, Ipronidazole, proplatin, Iproxamine Hydrochloride, Gabapentin, Gadobenate Dimeglumine, gadobenic acid, , irbesartan, irinotecan, irloxacin, iroplact, irsogla gadobutrol, Gadodiamide, gadolinium texaphyrin, Gadopen din, Irtemazole, isalsteine, Isamoxole, isbogrel, Isepamicin, tetate Dimegiumine, gadoteric acid, Gadoteridol, Gadover isobengaZole, Isobutamben, , , Iso setamide, , galdansetron, Galdansetron Hydro 40 etharine, isofloxythepin, Acetate, , chloride, , gallium nitrate, , Isofluorophate, isohomohalicondrin B, Isoleucine, Isoma galocitabine, Gamfexine, gamolenic acid, Ganciclovir, Zole Hydrochloride, Isomylamine Hydrochloride, , ganirelix, Gemcadiol, Gemcitabine, , Gemfi Iodide, , isopropyl unopros brozil, Gentamicin Sulfate, Gentian Violet, , Gesta tone, Isoproterenol Hydrochloride, Isosorbide, Isosorbide clone, , , , Gev 45 Mononitrate, Isotiquimide, , Isoxepac, , otroline Hydrochloride, , glargine insulin, Hydrochloride, , itameline, itasetron, glaspimod, Glatiramer, glaucocalyxin A, , Glia ItaZigrel, , , , ixabepilone, jas milide, , Glicetanile Sodium, Glifiumide, plakinolide, Jemefloxacin, Jesopitron, Josamycin, kahalalide , , Gloximonam, , glutapy F. Kalafungin, Kanamycin Sulfate, ketamine, , rone, , Glyburide, glycopine, glycopril, Glyco 50 , , Kethoxal, Ketipramine Fumarate, pyrrolate, Glyhexamide, Glymidine Sodium, Glyoctamide, , , , ketorolac, Glyparamide, Gold Au-198, Gonadoctrinins, Gonadorelin, Fumarate, Kitasamycin, Hydrochloride, Lacid , Goserelin, , , grepa ipine, , lactitol, lactivicin, Lactobionate, laennec, floxacin, , Guaiapate, Guaithylline, , , 1-alphahydroxyvitamin D2, lamellarin-N triac Guanabenz, Acetate, Sulfate, Guancydine, 55 etate, lamifiban, Lamivudine, Lamotrigine, lanoconazole, Monosulfate, Hydrochloride, Lanoxin, , lanreotide, lanreotide acetate, Lanso Guanisoquin Sulfate, Sulfate, Guanoctine Hydro prazole, lapatinib, laropiprant, latanoprost, lateritin, lauroca chloride, , Sulfate, Guanoxyfen Sul pram, Lauryl Isoquinolinium Bromide, Succi fate, Gusperimus Trihydrochloride, , Halcinon nate, , Lecimibide, leinamycin, lemildipine, ide, halichondrin B. Halobetasol Propionate, halofantrine, 60 leminoprazole, lenercept, Leniquinsin, lenograstim, Lemper Halofantrine Hydrochloride, Halofenate, Halofuginone one, lentinan Sulfate, , leptolstatin, , Ler Hydrobromide, halomon, Halopemide, , halopre gotrile, , Letimide Hydrochloride, letraZuril, letro done, , , , Halquinols, Zole, , leucomyzin, leuprolide, Leuprolide Acetate, , hatomamicin, hatomarubigin A, hatomarubigin B, , Levalbuterol, Levamfetamine Succinate, levami hatomarubigin C, hatomarubigin D. Sodium, hep 65 sole, Levdobutamine Lactobionate, Leveromakalim, leveti sulfam, heregulin, , Heterooium Bromide, , Levey closerine, , , Hexachlorophene Hydrogen Peroxide, Hexafluorenium Bro , , levocarnitine, levocetirizine, US 8,480,637 B2 37 38 levocetirizine dihydrochloride, Levodopa, , Sodium, merbarone, Mercaptopurine, Mercufenol Chloride, levofloxacin, Levofuraltadone, Levoleucovorin Calcium, Merisoprol, Meropenem, Mesalamine, MeseclaZone, Levomethadyl Acetate, Levomethadyl Acetate Hydrochlo , , , Mesuprine Hydro ride, , Hydrochloride, Levonor chloride, Metalol Hydrochloride, Metaproterenol Polistirex, defrin, Levonorgestrel, Napsylate, Levo Bitartrate, Metaxalone, Meteneprost, meter propylcillin Potassium, , elin, Metformin, Chloride, Methacycline, Tartrate, , , Levothyroxine, methadone, MethadylAcetate, Methalthiazide, Methamphet Levothyroxine Sodium, Levoxadrol Hydrochloride, Lexi Hydrochloride, , Methazolamide, pafant, Lexithromycin, liarozole, LibenZapril, Lidamidine , Methenamine, Methenolone Acetate, Meth Hydrochloride, Lidocaine, Lidofenin, , Lifarizin, 10 etoin, Sodium, Methimazole, methioninase, Lifibrate, Lifibrol, Linarotene, Lincomycin, Linezolid, Methionine, Methisazone, Methixene Hydrochloride, Linogliride, , linotroban, , lintitript, , Sodium, Methopholine, lintopride, Liothyronine I-125, liothyronine sodium, Liotrix, , Methotrimeprazine, methoxatone, methoxy lirexapride, Lisdexamfetamine Dimesylate, lisinopril, Lispro polyethylene glycol-epoetin beta, , MethSux insulin, lissoclinamide, Lixazinone Sulfate, lobaplatin, 15 imide, Methyclothiazide, Methyl Palmoxirate, Methylatro Lobenzarit Sodium, Lobucavir, locarmate Meglumine, locar pine Nitrate, Methylbenzethonium Chloride, , mic Acid, locetamic Acid, lodamide, Lodelaben, lodipamide Methyldopate Hydrochloride, , Methyler Meglumine, lodixanol, Iodoantipyrine I-131, Iodocholesterol gonovine Maleate, methylhistamine, methylinosine mono I-131. Iodohippurate Sodium I-131, Iodopyracet I-125, phosphate, Methylphenidate, , Methylt Iodoquinol, Iodoxamate Meglumine, , Iodox estosterone, Methynodiol Diacelate, , amie Acid, Lofemizole Hydrochloride, , Methysergide Maleate, , , Metioprim, Hydrochloride, lofetamine Hydrochloride metipamide, , Hydrochloride, Met I-123, Hydrochloride, loglicic Acid, loglucol, kephamid Acetate, , Iodide, loglucomide, loglycamic Acid, logulamide, lohexyl, lombri , Metolazone, , Metoprine, Meto cine, , , lomethin I-125, Lometraline 25 prolol, Metoprolol tartrate, Metouizine, metrifonate, Metri Hydrochloride, lometrexol, Lomofungin, Lomoxicam, Zamide, Metrizoate Sodium, Metronidazole, Meturedepa, Lomustine, Lonapalene, , , lopamidol. , Metyrosine, Hydrochloride, lopanoic Acid, Hydrochloride, lophendylate, Mexrenoate Potassium, , Hydrochlo Lopinavir, loprocemic Acid, lopronic Acid, lopydol, lopy ride, , Mibefradil Dihydrochloride, , done, , Hydrochloride, loratadine, 30 michellamine B, , microcolin A, , Mida Lorazepam, , Lorcamide Hydrochloride, Lore Zolam Hydrochloride, , , Mifobate, clezole, Loreinadol, , Lorimetazepam, Lornoxi miglitol, millacemide, , mildronate, Milenperone, cam, , , LorZafone, losartan, Losartan Milipertine, , , , Mimbane potassium, losefamic Acid, loseric Acid, losigamone, losox Hydrochloride, , , Minocromil, antrone, loSulamide Meglumine, Losulazine Hydrochloride, 35 Minocycline, Minocycline hydrochloride, , losumetic Acid, lotasul, , lotetric Acid, lothala Mioflazine Hydrochloride, miokamycin, mipragoside, mir mate Sodium, lothalamic Acid, lotrolan, lotroxic Acid, lov fentanil, mirimostim, Mirincamycin Hydrochloride, astatin, loversol, loviride, loXagiate Sodium, loxaglate Mirisetron Maleate, , Misonidazole, Misopros Meglumine, loxaglic Acid, , Loxoribine, loxotri tol, Mitindomide, Mitocarcin, Mitocromin, Mitogillin, Zoic Acid, , Lucanthone Hydrochloride, Lufironil, 40 mitoguaZone, mitolactol, Mitomalcin, Mitomycin, mitona Lurosetron Mesylate, lurtotecan, lutetium, Lutrelin Acetate, fide, Mitosper, Mitotane, mitoxantrone, mivacurium chlo luZindole, Lyapolate Sodium, Lycetamine, lydicamycin, ride, , mixanpril, Mixidine, , mizorib Lydimycin, , Lypressin, , lysofylline, lyso ine, , modafinil, Modaline Sulfate, staphin, Maduramicin, , magainin2 amide, Magne Modecamide, moexipril, mofarotene, Hydro sium Salicylate, Sulfate, , maitansine, 45 chloride, , molgramostim, MolinaZone, Molin Malethamer, mallotoaponin, mallotochromene, Malotilate, done Hydrochloride, , mometasone, malotilate, mangafodipir, , maniwamycin A, Maleate, Monensin, Monoctanoin, montelukast, Mon , mannostatin A, manumycin E, manumycin F. telukast Sodium, montirelin, mopidamol, , Mor mapinastine, , maraviroc, marimastat, Marinol, antel Tartrate, Moricizine, , Morphine, Mor Masoprocol, maspin, massetolide, Maytansine, 50 rhuate Sodium, , , motilide, Succiniate, , Mebendazole, Hydro Motretinide, Moxalactam Disodium, , Moxi chloride, Mebrofenin, , Hydro floxacin, moxiraprine, MoXnidazole, , Mumps chloride, Mechlorethamine Hydrochloride, meclizine hydro Skin Test Antigen, Muzolimine, mycaperoxide B, Mycophe chloride, Meclocycline, Meclofenamate Sodium, nolate mofetil, , myriaporone, Nabazenil, , Dibutyrate, Hydro 55 , Hydrochloride, Naboctate Hydrochloride, chloride, Medorinone, , , Medrox , N-acetyldinaline, Nadide, , Nad yprogesterone, , Meelizine Hydrochloride, Mefe olol, , , nafamo.stat, nafarelin, namic Acid, Mefenidil, Hydrochloride, Sodium, , Nafimidone Hydrochloride, , Hydrochloride, Mefruside, Mega , Nafomine Malate, Hydrochloride, lomicin Potassium Phosphate, Acetate, Meglu 60 Nafronyl Oxalate, Hydrochloride, , nagli mine, , Acetate, Meloxicam, Mel van, nagrestip, Hydrochloride, Nalidixate phalan, Memantine, Memotine Hydrochloride, Menabitan Sodium, , , Hydrochlo Hydrochloride, Menoctone, menogaril, Menotropins, ride, naloxone, , Namoxyrate, Phen Meobentine Sulfate, , Bromide, propionate, Nantradol Hydrochloride, Napactadine Hydro Meperidine Hydrochloride, Sulfate, Mephe 65 chloride, napadisilate, Napamezole Hydrochloride, napavin, nyloin, Mephobarbital, Hydrochloride, Mep Hydrochloride, naphterpin, Naproxen, robamate, Hydrochloride, Mequidox, Meralein Naproxen Sodium, NaproXol, napsagatran, Hydro US 8,480,637 B2 39 40 chloride, Narasin, , nartograstim, nasaruplase, , Partricin, Paulomycin, pazelliptine, Pazina natalizumab, , nateplase, Naxagolide Hydrochlo clone, PaZoxide, , , pegaspargase, ride, , Nebramycin, nedaplatin, , Nefa Pegorgotein, Pegylated interferon alfa-2a, Hydro Zodone Hydrochloride, Neflumozide Hydrochloride, Nefo chloride, peldesine, Peliomycipelretin, Pelrinone Hydrochlo pam Hydrochloride, NeleZaprine Maleate, Nemazoline ride, Pemedolac, Pemerid Nitrate, Pemetrexed, , Hydrochloride, nemorubicin, Palmitate, Neostig , , Sulfate, Penciclovir, mine Bromide, neridronic acid, Netilmicin Sulfate, Neutra , Penicillamine, Penicillin G BenZathine, Penicil mycin, Nevirapin Hydrochloride, Niacin, lin G Potassium, Penicillin G , Penicillin G Sodium, Nibroxane, Hydrochloride, , Penicillin V Hydrabamine, Penicillin V BenZathine, Penicil Niclosamide, , , , 10 lin V Potassium, , Pentaerythritol Tetranitrate, Nifedipine, Nifirmerone, Nifluridide, Nifuradene, Nifurald pentafuside, , , Pentamustine, eZone, , Nifuratrone, Nifurdazil, Nifurimide, Pentapiperium Methylsulfate, , Pentetic Acid, Nifurpirinol, Nifurcquinazol, Nifurthiazole, Nifurtimox, nilo Pentiapine Maleate, pentigetide, Pentisomicin, Pentizidone tinib, nilotinib hydrochloride monohydrate, , Nil Sodium, , , Pentopril, pentosan, pen Vadipine, NimaZone, , , , 15 tostatin, , Pentrinitrol, pentrozole, Peplomycin Niridazole, nisamycin, Nisbuterol Mesylate, nisin, Nisobam Sulfate, Pepstatin, perflubron, perfofamide, Perfosfamide, ate, , Nisoxetin Acetate, Nitarsone, , Perhexyline Maleate, perillyl alcohol, Perindopril, , , Nitrafudam Hydrochloride, perindoprilat, Perlapin , , Perphena Nitralamine Hydrochloride, Nitramisole Hydrochloride, Zine, , , phenazinomycin, , , Nitrocydine, Nitrodan, Nitro Hydrochloride, Phenbutazone Sodium furantoin, Nitrofurazone, Nitroglycerin, Nitromersol, Nitro Glycerate, Phencarbamide, Hydrochloride, mide, Citrate, , nitroxide antioxi Tartrate, Sulfate, Phenformin, dant, nitrullyn, Nivazol, Nivinedone Sodium, , Hydrochloride, , Phenoxyben Noberastine, Nocodazole, Nogalamycin, Nolinium Bromide, Zamine Hydrochloride, , phenserine, phen Maleate, Hydrochloride, Nor 25 succinal, , , Phentermine Hydro bolethone, Bitaritrate, Norethindrone, Nor chloride, mesilate, Phentoxifylline, Phenyl ethynodrel, Norfurane, , , Norg Aminosalicylate, phenylacetate, , phenylala estomet, , Nortriptyline Hydrochloride, nylketoconazole, , Hydro , Nylestriol, Nystatin, Obidoxime chloride, Hydrochloride, Phenylpro Chloride, , Hydrochloride, Ocina 30 panolamine Polistirex, Phenyramidol Hydrochloride, plon, Octanoic Acid, Octazamide, Octenidine Hydrochlo Phenyloin, Phenyloin Sodium, Physostigmine, , ride, , , Phosphate, Ofloxa picibanil, Picotrin Diolamine, picroliv, picumeterol, pidoti cin, Ofornine, okicenone, Olanzepine, Olmesartan, mod, Pifarnine, , pilsicamide, , Pimet olmesartan medoxomil, olopatadine, olopatadine hydrochlo ine Hydrochloride, pimilprost, , , Pina ride, , olsalazine, Olsalazine Sodium, Olvanil, 35 cidil, Pinadoline, , pinnenol, pinocebrin, Omalizumab, Omega-3 acid ethyl esters, omeprazole, Hydrochloride, pioglitaZone, , Pipazethate, , ondansetron, Ontazolast, Oocyte , , Piperacillin, Piper Hydrochloride, oracin, Orconazole Nitrate, Orgotein, Orlis acillin Sodium, Piperamide Maleate, piperazinc, Pipobro lat, Ormaplatin, Ormetoprim, , Orpanoxin, man, Piposulfan, Palmitate, Pipoxolan Hydro Citrate, , Oseltamivir, , 40 chloride, Piprozolin, Hydrochloride, Piquizil Sodium, Oxagrelate, oxaliplatin, Oxamarin Hydro Hydrochloride, , Hydrochloride, pira chloride, oxamisole, Oxamniquine, , Oxantel rubicin, PiraZmonam Sodium, Pirazolac, Pirbenicillin Pamoate, Hydrochloride, , Oxarba Sodium, Acetate, , Zole, , oxaunomycin, , oXcarbazepine, Hydrochloride, , Pirfenidone, Piridicillin Sodium, , Oxethazaine, Fumarate, Oxfenda 45 Piridironate Sodium, Piriprost, piritrexim, Pirlimycin Hydro Zole, Oxfenicine, Oxibendazole, , , chloride, , pirmagrel, Pirmenol Hydrochloride, Oxidronic Acid, Oxifungin Hydrochloride, , Oxi Pirnabine, Piroctone, Pirodavir, pirodomast, Pirogliride Tar monam, Oximonam Sodium, OXiperomide, , trate, , Pirolazamide, Piroxantrone Hydrochloride, Oxiramide, Oxisuran, Hydrochloride, oxo , Piroximone, , Pirquinozol, Pirsidomine, dipine, Phenopropionate, , Oxpre 50 Hydrochloride, Pivopril, Pizotyline, placetin A, nolol Hydrochloride, Oxtriphylline, Chloride, , , Pobilukast Edamine, Podofilox, Oxychlorosene, Oxycodone, oxycodone hydrochloride, Poisonoak Extract, Methylsulfate, Poliglusam, Hydrochloride, , Oxymor Polignate Sodium, B Sulfate, Polythiazide, phone Hydrochloride, , , Oxy Ponalrestat, Porfimer Sodium, Porfiromycin, Potassium purinol, , Oxytocin, , Ozlinone, Pacli 55 Chloride, , Potassium Permanganate, Povi taxel, palauamine, Paldimycin, palinavir, Palivizumab, done-Iodine, , Pralidoxime Chloride, Pramipexole, palmitoylrhizoxin, Palmoxirate Sodium, pamaqueside, Hydrochloride, Pramoxine Hydrochloride, Sulfate, , Pamidronate Disodium, pam Pranolium Chloride, Pravadoline Maleate, Pravastatin, Prav idronic acid, , , panaxytriol, Panco astatin sodium, , , Prazosin Hydrochloride, pride, , , pannorin, 60 , , , Prednisolone, , pantethine, pantoprazole, Hydro prednisolone quetiapine fumerate, , Prednival, chloride, parabactin, paracetamol, Parachlorophenol, Paral Pregabalin, Succiniate, Hydrochlo dehyde, Acetate, Paranyline Hydrochloride, ride, , Hydrochloride, Prifelone, Prilo Parapenzolate Bromide, Pararosaniline Pamoate, Parbenda calne Hydrochloride, Prilosec, Primaquine Phosphate, Primi Zole, Parconazole Hydrochloride, , Pareptide Sul 65 dolol, , Prinivil, Prinomide Tromethamine, fate, Hydrochloride, , Paromo Prinoxodan, pritosufloxacin, Prizidilol Hydrochloride, mycin Sulfate, Paroxetine, paroxetine hydrochloride, Hydrochloride, Probenecid, Probicromil Calcium, US 8,480,637 B2 41 42 , Hydrochloride, Procaine Hydro cin, rupatidine, Rutamycin, ruzadolane, , Safingol. chloride, Hydrochloride, Hydro safironil, saintopin, Salbutamol, Salbutamol Sulfate, Salcolex, chloride, , , Proclonol, Procy Salethamide Maleate, Salicyl Alcohol, , Salicy clidine Hydrochloride, Hydrochloride, Prodolic late Meglumine, , Salmeterol, Salnacediin, Sal Acid, Hydrochloride, , Progesterone, Pro salate, , Sampatrilat, Sancycline, Sanfetrinem, glumide, Proinsulin (human), , Hydrochlo Sanguinarium Chloride, Saperconazole, Saprisartan, saprop ride, Hydrochloride, Promethazine, Promethaz terin, sapropterin dihydrochloride, saquinavir, ine hydrochloride, Hydrochloride, Hydrochloride, Saralasin Acetate, sarcophytol A, sargra propagermanium, , , Pro mostim, Sarmoxicillin, Sarpicillin, , , paracaine Hydrochloride, Propatyl Nitrate, , 10 saterinone, satigrel, Satumomab pendetide, Scopafungin, Propenzolate Hydrochloride, Propikacin, , Hydrobromide, Scrazaipine Hydrochloride, , propionylcarnitine, , propiram, Secalciferol, , Seelzone, segiline, Seglitide , , Proponolol hydrochloride, Pro Acetate, Hydrochloride, Sulfide, Sele poxycaine Hydrochloride, Propoxyphene Hydrochloride, nomethionine Se-75, , sematilide, semduramicin, Hydrochloride, Propulsid, propylbis-acridone, 15 semotiadil, semustine, Sepazonium Chloride, Seperidol , Propyliodone, Propylthiouracil, Proqua Hydrochloride, Seprilose, Hydrochloride, Zone, Prorenoate Potassium, Proroxan Hydrochloride, Seractide Acetate, Maleate, , Sermetacin, Proscillaridin, Prostalene, prostratin, Protamine Sulfate, pro Sermorelin Acetate, , , Sertraline, Ser tegrin, Protirelin, Hydrochloride, , traline hydrochloride, S-ethynyluracil, , Setoper Proxazole Citrate, Proxicromil, Tartrate, pruli one, Sevelamer, Sevirumab, sevoflurane, Sezolamide, floxacin, pseudoephedrine, Pseudophedrine hydrochloride, Sibopirdine, Hydrochloride, , , Pyrabrom, Pamoate, Pyrazinamide, Sildenafil, sildenafil citrate, silipide, silteplase, Silver Nitrate, Pyrazofurin, pyrazoloacridine, Pyridostigmine Bromide, simendan, SimtraZene, Simvastatin, Sincalide, Sinefungin, Pyridoxine hydrochloride, Pyrilamine Maleate, Sinitrodil, sinnabidol, sipatrigine, , Sisomicin, Sita Pyrimethamine, Pyrinoline, Pyrithione Sodium, Pyrithione 25 gliptin, Sitogluside, sizofuran, Sobuzoxane, Sodium Amylo , Hydrochloride, Pyroxamine Maleate, sulfate, Sodium Iodide I-123, Sodium Nitroprusside, Sodium Pyrrocaine, Pyrroliphene Hydrochloride, Pyrrolnitrin, Pyrv Oxybate, sodium phenylacetate, , Sodium inium Pamoate, Mesylate, , Quazi valproate, Solifenacin, solverol, Solypertine Tartrate, Soma none, QuaZodine, QuaZolast, quetiapine, quetiapine fuma lapor, Somantadine Hydrochloride, B, rate, quiflapon, , Quinaldine Blue, quinapril, 30 Somatomedin C. Somatostatin, Somatrem, somatropin, Quinapril hydrochloride, Hydrochloride, Quin Somenopor. Somidobove, Sorbinil, Sorivudine, , bolone, Quinctolate, Quindecamine Acetate, Quindonium Soterenol Hydrochloride, Sparfioxacin, Sparfosate Sodium, Bromide, Hydrochloride, , Quinfa sparfosic acid, Sparsomy, Sulfate, Spectinomycin mide, Acetate, , Glu Hydrochloride, spicamycin D. , Mesy conate, Quinielorane Hydrochloride, Sulfate, Quin 35 late, Spiramycin, Spirapril Hydrochloride, Spiraprilat, pirole Hydrochloride, Quinterenol Sulfate, Quinuclium Spirogermanium Hydrochloride, Spiromustine, Spironolac Bromide, Quinupristin, Maleate, Rabeprazole, tone, Spiroplatin, , splenopentin, Spongistatin, Rabeprazole Sodium, Racephenicol, Racepinephrine, Rafox Sprodiamide, squalamine, Stallimycin Hydrochloride, Stan anide, Ralitoline, raloxifene, raltegravir, raltitrexed, rama nous Pyrophosphate, Stannous Colloid, , troban, Ramipril, , , ranelic acid, 40 Statolon, staurosporine, stavudine, Steffimycin, Ranimycin, Ranitidine, Ranitidine hydrochloride, ranola Acetate, , Stilbazium Iodide, Stilonium Iodide, Zine, Rauwolfia Serpentina, recainam, Recainam Hydrochlo stipiamide, , stobadine, Streptomycin Sulfate, ride, , Recombinant factor VIII, regavirumab, Streptonicozid, Streptonigrin, Streptozocin, Chlo Regramostim, , Relomycin, Hydro ride Sr-89, succibun, Succimer. Succinylcholine Chloride, chloride, Hydrochloride, Remiprostol, Remox 45 Sucralfate. Sucrosofate Potassium, Sudoxicam, , ipride, Repirinast, Repromicin, Hydrochloride, , , Pivoxil, , resinferatoxin, Resorcinol, retapamulin, retellip Nitrate, Sulfabenz, Sulfabenzamide, , Sulfacy tine demethylated, reticulon, , revizinone, tine, , , , , rhenium etidronate, rhizoxin, RI retinamide, Ribaminol, Rib Sulfameter, Sulfamethazine, , Sulfamethox avirin, Riboprine, , Ridogrel, , Rifamet 50 , Sulfamonomethoxine, , Sulfanilate Zinc, ane, Rifamexil, Rifamide, Rifampin, , , , sulfasalazine, Sulfasomizole, Sulfazamet, Sulfi rilopirox, , , Hydrochloride, malol Hydrochloride, sulfinosine, , Sulfisox , Hydrobromide, Rimonabant, rimo azole, Sulfomethoxazole, Sulfomyxin, Sulfonterol Hydro progin, , Rioprostil, , ripisartan, Risedr chloride, sulfoxamine, Sulinldac, Sulmarin, Sulnidazole, onate, Risedronate Sodium, risedronic acid, , Riso 55 , Sulofenur, Sulopenem, Suloxifen Oxalate, tilide Hydrochloride, rispenzepine, Risperdal, Risperidone, , , , Sulthiame, , , , , Ritolukast, ritonavir, ritux Sulukast, Sumarotene, Sumatriptan, Sumatriptan Succinate, imab, rivastigmine, rivastigmine tartrate, Rizatriptan, riza Suncillin Sodium, , , Suradista, , benzoate, Rocastine Hydrochloride, Rocuronium Surfomer, Suricamide Maleate, Suritozole, Suronacrine Bromide, Rodocaine, , Rogletimide, rohitukine, 60 Maleate, Suxemerid Sulfate, Swainsonine, Symakalim, Sym rokitamycin, Roletamicide, Rolgamidine, Rolicyprine, closene, Symetine Hydrochloride, Taciamine Hydrochloride, , Rolitetracycline, Rolodine, Romazarit, romurtide, Hydrochloride, Tacrolimus, Tadalafil. Ronidazole, Ropinirole, Ropitoin Hydrochloride, ropiv Hydrochloride, , Talisomycin, tallimustine, Tal acaine, Ropizine, roquinimex, Rosaramicin, rosiglitaZone, metacin, Talniflumate, Hydrochloride, Talosalate, RosiglitaZone maleate, , Rosuvastatin, Rotavirus 65 Hydrochloride, Tamoxifen, tamoxifen citrate, vaccine, rotigotine, Rotoxamine, roXaitidine, Roxarsone, Fumarate, Tamsulosin, Tamsulosin Hydrochlo , , rubiginone B1, ruboxyl, rufloxa ride, Hydrochloride, , tapgen, tap US 8,480,637 B2 44 rostene, Tasosartan, tauromustine, Taxane, Taxoid, Tazad triflavin, Triflocin, , Triflumidate, Trifluopera olene Succinate, tazanolast, tazarotene, Tazifylline zine Hydrochloride, , , Triflu Hydrochloride, , Tazofelone, Hydrochlo promazine Hydrochloride, Trifluridine, ride, Tebufelone, Tebuquine, , Tecogalan Sodium, Hydrochloride, , Hydrochloride, tri Teecleukin, , Tegafur, Tegaserod, Tegretol, Teico megestone, Trimeprazine Tartrate, , Tri planin, , tellurapyrylium, telmesteine, telmisar methaphan Camsylate, Trimethoprim, , Trimetr tan, Teloxantrone Hydrochloride, Teludipine Hydrochloride, eXate, , Trimoprostil, Trimoxamine Hydrochloride, Tematropium Methyl sulfate, Hydrochloride, Triolein, Mesylate, Tripamide, Temazepam, Temelastine, temocapril, , temopor Hydrochloride, Hydrochloride, fin, temozolomide, temsirolimus, , Teniposide, Teno 10 Triptorelin, Trisulfapyrimidines, Troclosene Potassium, tro fovir, tenosal, , tepirindole, , Teprotide, glitaZone, Trolamine, , trombodipine, terazosin, Terazosin Hydrochloride, Terbinafine, trometamol, Hydrochloride, , Sulfate, , , terfiavoxate, , tropine, , trospectomycin, , troVird , Teriparatide Acetate, terlakiren, terlipressin, ine, , Tuberculin, , Tubulo , Teroxalene Hydrochloride, Teroxirone, . 15 Zole Hydrochloride, tucarcsol, , , Tesicam, Tesimide, , Testosterone, , , tylogenin, Tyropanoate Sodium, , Tyro tetrachlorodecaoxide, Tetracycline, Tetracycline hydrochlo thricin, tyrphostins, , , Undecylenic ride, Tetrahydrozoline Hydrochloride, Tetramisole Hydro Acid, Mustard, , , Uredepa, triph chloride, Tetrazolast Meglumine, tetrazomine, Tetrofosmin, osphate, , , Ursodiol, Valaciclovir, Tetroquinone, , Tetrydamine, thaliblastine, Tha Valacyclovir hydrochloride, Valine, , Valproate lidomide. Theofibrate. . Thiabendazole. Thia semisodium, Valproic Acid, Valsartan, Vamicamide, vana miprine. . . Thiazesim Hydrochlo deine, , Vaminolol, Vapiprost Hydrochloride, ride. Thiazinamium Chloride. . Thiithixene, Vapreotide, Vardenafil. Varenicline, variolin B. Vasopressin, Thimerfonate Sodium, Thimerosal, thiocoraline, thiofedrine, , velaresol, Velnacrine Maleate, ven Thioguanine, thiomarinol. Thiopental Sodium, thioperam 25 lafaxine, Venlafaxine hydrochloride, Veradoline Hydrochlo ide. . Thiotepa, Thiphenamil Hydrochloride, ride, Veramine, Verapamil Hydrochloride, verdins, Verilopam Thiphencillin Potassium, Thiram, . , Hydrochloride, Verlukast, Verofylline, Veroxan, verteporfin, , thrombopoietin, thymalfasin, thymopentin, thy , Vexibinol, Vidarabine, , Vildagliptin, motrinan, Thyromedan Hydrochloride, Thyroxine, Tiacrilast, Hydrochloride, Vinblastine Sulfate, Tiacrilast Sodium, , , , 30 citrate, Vincofos, Vinconate, Vincristine Sulfate, Vindesine, tiapafant, Tiapamil Hydrochloride, Tiaramide Hydrochlo Vindesine Sulfate, Vinepidine Sulfate, Vinglycinate Sulfate, ride, Tiazofurin, Tibenelast Sodium, , Tilbric Acid, Vinleurosine Sulfate, vinorelbine, , Vintoperol, Propionate, Ticarbodine, Cresyl vinxaltine, Vinzolidine Sulfate, Viprostol, Virginiamycin, Sodium, , , Ticrynafen, , Tifu Viridofulvin, Viroxime, vitaxin, Voglibose, , Vori rac Sodium, Dicholine, , 35 conazole, Vorozole, Voxergolide, Wafarin, , Hydrochloride, Hydrochloride, , tilnoprofe , Xanoxate Sodium, Niacinate, narbamel, Tilorone Hydrochloride, Tiludronate Disodium, Xemiloflban, Xenalipin, Xenbucin, Xilobam, Ximoprofen, tiludronic acid, Timefurone, Acetate, Timolol, Xipamide, Mesylate, Tosylate, Xyla Timolol meleate, Tinabinol, Timidazole, , zine Hydrochloride, Hydrochloride, xylose, , , Tiodonium Chloride, Tioperidone 40 yangambin, Zabicipril, , , Zalcitabine, Hydrochloride, Tiopinac, Hydrochloride, Tioti Zaleplon, , Zaltidine Hydrochloride, , dine, Tiotropium, , Tioxidazole, Tipen Zanamivir, Zankiren, , Zantac, Zarirlukast, Zate tosin Hydrochloride, tipranavir, , bradine, , Zatosetron Maleate, Zenarestat, ZenaZo Hydrochloride, Tiprinast Meglumine, Tipropidil Hydrochlo cine Mesylate, Zeniplatin, , Zidometacin, Zidovu ride, Tiqueside, Tiquinamide Hydrochloride, tirandalydigin, 45 dine, Zifrosilone, Zilantel, Zilascorb, , Zimeldine Tirapazamine, , , , titanocene Hydrochloride, Zinc Undecylenate, Zindotrine, Zinocona dichloride, Tixanox, Pivalate, Hydro Zole Hydrochloride, Zinostatin, Hydrochloride, Zin chloride, Tnmethobenzamide Hydrochloride, Tobramycin, viroxime, ziprasidone, Zobolt, Zofenopril Calcium, Zofeno Tocamide, Tocamphyl, Hydrochloride, , prilat, Hydrochloride, Hydrochloride, , Hydrochloride, , Tolca 50 Zoledronate, Hydrochloride, , Zolpi pone, , Tolfamide, Tolgabide, Tolimidone, Tolin dem, Sodium, , ZonicleZole Hydro date, Tolimetin, , TolpoVidone, Tolpyrramide, Tolr chloride, , , Zopolrestat, Zorbamycin, estat, Tolterodine, tolterodine tartrate, Tomelukast, Zorubicin Hydrochloride, , Zucapsaicin, and phar Tomoxetine Hydrochloride, Mesylate, Topira maceutically acceptable salts thereof. mate, topotecan, Topotecan Hydrochloride, top sentin, 55 , Toquizine, torasemide, , Torsemide, Example 1 Tosifen, , totipotent stem cell factor (TSCF). , trafermin, , , Tramadol The capsule as described herein is used to administer leu Hydrochloride, Hydrochloride, trandolapril, prolide acetate for the treatment of prostate cancer. Leupro Tranexamic Acid, Tranilast, Transcamide, trastuzumab, traX 60 lide acetate (USP31) is a synthetic nonapeptide agonistana anox, Trazodone Hydrochloride, Trebenzomine Hydrochlo log of -releasing factor (LNHR). The ride, Hydrochloride, Treloxinate, leuprolide acetate molecule is approximately 1209 Daltons in Maleate, Acetate, tretinoin, Triacetin, triacetylu weight and two to three nanometers in size. It is soluble in ridine, Triafungin, , Triampyzine Sulfate, Tri aqueous media at a level of approximately 10 mg/mL. An amterene, , Tribenoside, tricaprilin, Tricetamide, 65 existing method of administering leuprolide via extended Trichlormethiazide, trichohyalin, triciribine, Tricitrates, Tri release is disclosed in U.S. Pat. No. 5,728,396 filed Jan. 30, clofenol , Sodium, trientine, Trifenagrel, 1997 and incorporated herein by reference. US 8,480,637 B2 45 46 The nanochannel delivery device chip is installed in a approach for reducing growth-stimulatory effects of estro capsule as described herein and filled with a 5 mg/mL leu gens in estrogen-dependent breast cancer, which constitutes prolide acetate solution (NDC number 0703-4014-18) for use approximately 60-70% of breast cancer. Among the aro in the treatment of prostate cancer. The capsule is sized to matase inhibitors, letrozole is a highly potent non-steroid approximately 2.8 mL, so that the filled capsule contains inhibitor which inhibits approximately 99% of estrogen bio approximately 14 mg of leuprolide acetate. If stronger con synthesis. Additionally, several studies and clinical trials on of metastatic breast cancer indicated higher centrations of leuprolide acetate Solution are used, the capsule efficacy with fewer side effects of letrozole when compared to Volume may be correspondingly reduced. The capsule is Tamoxifen. Hence, research Suggests letrozole as a candidate implanted Subcutaneously in the inner portion of the upper for the development of chemopreventive therapy for women arm or upper leg or in the abdomen. The capsule is implanted, 10 at increased risk of breast cancer. However, the conventional with optional use of a tissue separator, through a small inci oral administration of letrozole showed increased risk of heart sion in a clinical outpatient procedure and removed two to problems and osteoporosis. The key for the Success of chemo three months later through a small incision. For implant and prevention for breast cancer relies on long term delivery of explant, a Small amount of anesthetic is used, for example, a specific drugs while circumventing side effects. As opposed 1% lidocaine injection at the site. 15 to the inefficient oral administration, a constant local release The micro- and nano-channel sizes of the nanochannel of chemopreventive agent (i.e. letrozole) in breast tissue delivery device are chosen (for example, according to the could significantly reduce occurrence of breast tumor as well model described in Grattoni, A. Ferrari, M., Liu, X. Quality as Systemic side effects. This shows promise for improvement control method for micro-nano-channels silicon devices. in patient quality of life. U.S. Patent Application No. 61/049.287 (April 2008)), to It is believed that the implantable nanochanneled devices provide a release rate of about 120 ug/day can be obtained for according to the present disclosure will allow the constant and about 90 days in certain embodiments. Sustained local release of letrozole in breast tissues and sig In this example, the nanochannel delivery device configu nificant reduction of estrogen dependent epithelial cell pro ration with this behavior uses a 6x6 mm chip size, with 161 liferation with minimum toxicities. macrochannels with openings of 190x 190 um each, and 25 Prior clinical trials employed letrozole daily doses of 2.5 mg. It is believed that the constant local release of letrozole in within each macrochannel approximately 23 rows of breast tissues (utilizing nanochanneled devices according to nanochannel structures, consisting of 10 each of inlet and the present disclosure) would require lower dosage if com outlet microchannels, connected through about 20 nanochan pared to oral delivery. In first analysis it is believed that a local nels according to the description herein. The inlets and outlets daily release in the range 25 to 50 ug could be effective. are approximately 5x5 um in cross-section, with the inlets 30 The achievement of an efficient chemopreventive therapy being about 30 um long and the outlets being about 1.6 um by the use of long-term, constant release implants for local long, and the nanochannels are about 5 m long and 5 um administration of chemopreventive agents will have signifi wide and 13 nm high. Other configurations with different cant impact on the quality of life of women in the high risk dimensions may be derived from the mathematical model that group. It is believed that use of nanochannel delivery devices yield approximately the same release rate and duration in 35 according to the present disclosure will lead to improved other examples. efficacy of therapy, as well as potential reduction of drug doses and reduction of side effects through true constant Example 2 release. A reduction in the number of breast cancer occur rences due to effective preventive therapy would also have a The capsule and nanochannel delivery device are config 40 positive economic impact on patients, their employers and ured and implanted as described in Example 1. However, insurers through lowered cost of treatment, fewer medical instead of administering leuprolide acetate, the capsule and visits, and less work time lost. nanochannel delivery device administer letrozole for the The development of a reliable extended release implant treatment of breast cancer. The limited success of chemo able technology adds a new dimension to drug delivery for therapy for the treatment of breast cancer emphasizes the 45 breast cancer. Tumor treatment and the Suppression of metastasis and/or tumor recurrence are natural follow-on need of novel preventive strategies to minimize the cancer developments. Technology enhancements to the initial plat occurrence. Recent studies have highlighted that form could support variable and programmed release, includ inhibitors are promising chemopreventive agents for breast ing remote, interactive control of the implanted device, fur cancer through inhibition of estrogen biosynthesis. In par ther enabling capabilities to deploy multiple drugs ticular, research has suggested that letrozole is an ideal can 50 simultaneously. In vivo refilling could also extend the func didate for chemoprevention for women in high risk group tionality of the nanochannel device and also decrease adverse such as BRCA1 positive. However, the low efficacy and the events associated with explanation. As a general drug deliv side effects associated with the conventional systemic admin ery method, other indications may be identified, broadening istration of letrozole are limiting factors for its long term the applicability of the innovation. uSage. 55 Breast cancer growth is highly dependent on estrogen, and Example 3 thus inhibition of estrogen is highly effective for the preven tion of breast tumor development. Recent studies have high The capsule and nanochannel delivery device are config lighted aromatase inhibitors such as anastroZole, letrozole, ured and implanted in a patient as described in Example 1. and exemestane, as promising molecules that can be used for 60 However, instead of administering leuprolide acetate, the chemoprevention of breast cancer. Aromatase mediates bio capsule and nanochannel delivery device administerlapatinib synthesis of estradiol, the most potent form of estrogen, from for the treatment of breast cancer. by the complex (Aro matase). Aromatase is present in breast tissue and the nonste Example 4 roidal and steroidal aromatase inhibitors reduce circulating 65 estrogen level to 1% to 10% of pretreatment levels, respec The capsule and nanochannel delivery device are config tively. Therefore, inhibition of aromatase is an important ured and implanted in a patient as described in Example 1. US 8,480,637 B2 47 48 However, instead of administering leuprolide acetate, the 5 Brueggemeier, R. W., Hackett, J. C., Diaz-Cruz, E. S. capsule and nanochannel delivery device administer bupe Aromatase Inhibitors in the Treatment of Breast Cancer. norphine for the treatment of opiate dependency. Endocrine Reviews 26,331-345 (2005). 6. Coates, A. S. Keshaviah, A., Thirlimann, B., et al. Five Example 5 5 years of letrozole compared with tamoxifen as initial adju vant therapy for postmenopausal women with endocrine The capsule and nanochannel delivery device are config responsive early breast cancer: update of study BIG 1-98.J. ured and implanted in a patient as described in Example 1. Clin. Oncol. 25, 486-492 (2007). However, instead of administering leuprolide acetate, the 7 Goss, P. E., Ingle, J. N., Martino, S., et al. A randomized capsule and nanochannel delivery device administer inter 10 trial of letrozole in postmenopausal women after five years feron alpha implant forgiant cell angioblastoma. of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349, 1793-1802 (2003). Example 6 8 Garreau, J. R., Delamelena, T., Walts, D., Karamlou, K., Johnson, N. Side effects of aromatase inhibitors versus The capsule and nanochannel delivery device are config 15 tamoxifen: the patients’ perspective. Am. J. Surg. 192, ured and implanted in a patient as described in Example 1. 496-8 (2006). However, instead of administering leuprolide acetate, the 9 Luthra, R., Kirma, N., Jones, J., Tekmal, R. R. Use of capsule and nanochannel delivery device administer Zidovu letrozole as a chemopreventive agent in aromatase overex dine in an intravaginal treatment for preventing HIV being pressing transgenic mice. The Journal of Steroid Biochem transmitted from a pregnant mother to a child. istry and Molecular Biology. 86, 461–467 (2003). As used herein, the term “direct fluid communication' is 10 Harper-Wynne, C., Ross, G., Sacks, N., Salter, J., Nasiri, interpreted as fluid communication between two bodies that N., Iqbal, J., A Hern, R., Dowsett, M. Effects of the aro are directly connected, e.g. Such that fluid may exit one body matase inhibitor letrozole on normal breast epithelial cell and immediately enter the second body without flowing proliferation and metabolic indices in postmenopausal through an intermediate body. For example, in the embodi 25 women: a pilot study for breast cancer prevention. Cancer ment shown in FIGS. 3A-3G, outlet 70 is in direct fluid Epidemiol. Biomarkers Prev. 11, 614-21 (2002). communication with nanochannel 25. However, outlet 70 is The invention claimed is: not in direct fluid communication withinlet 30, because fluid 1. A nanochannel delivery device comprising: must flow through an intermediate body (nanochannel 25) a planar body comprising a first Surface and a second after exiting inlet 30 and before entering outlet 70. 30 Surface opposing the first Surface; Furthermore, as used herein, the term “inlet' is interpreted an inlet microchannel; as a chamber or reservoir within a nanochannel delivery a nanochannel disposed within the planar body between device that initially retains a substance being delivered via the the first Surface and the second Surface; and nanochannel delivery device. Similarly, an “outlet' is inter an outlet microchannel, wherein the inlet microchannel preted as a chamber or reservoir within a nanochannel deliv 35 and the outlet microchannel are in direct fluid commu ery device that retains a Substance immediately prior to the nication with the nanochannel, wherein: Substance exiting the nanochannel delivery device. the inlet microchannel extends from the nanochannel to All of the devices, systems and/or methods disclosed and the first surface; claimed herein can be made and executed without undue the outlet microchannel extends from the nanochannel experimentation in light of the present disclosure. While the 40 to second the Surface; and devices, systems and methods of this invention have been the nanochannel is oriented parallel to the primary plane described in terms of particular embodiments, it will be of the nanochannel delivery device. apparent to those of skill in the art that variations may be 2. The nanochannel delivery device of claim 1, wherein a applied to the devices, systems and/or methods in the steps or flow path from the inlet microchannel to the nanochannel to in the sequence of steps of the method described herein with 45 the outlet microchannel requires a maximum of two changes out departing from the concept, spirit and scope of the inven in direction. tion. All Such similar Substitutes and modifications apparent 3. The nanochannel delivery device of claim 1, wherein the to those skilled in the art are deemed to be within the spirit, inlet microchannel has a length, a width, and a depth; Scope and concept of the invention as defined by the appended wherein the outlet microchannel has a length, a width, and claims. 50 a depth; wherein the nanochannel has a length, a width, and a depth; REFERENCES wherein the ratio of the nanochannel length to the inlet microchannel length is between 0.01 and 10.0; and The contents of the following references are incorporated wherein the ratio of the nanochannel length to the outlet by reference herein: 55 microchannel length is between 0.01 and 10.0. 1 Santen, R. J., Yue, W., Naftolin, F., Mor, G., Berstein, L. 4. The nanochannel delivery device of claim 3 wherein the The potential of aromatase inhibitors in breast cancer pre ratio of the nanochannel length to either the inlet microchan vention. Endocrine-Related Cancer: 6, 235-243 (1999). nel length or the outlet microchannel length is between 0.2 2 Goss, P. E., Strasser, K. Aromatase Inhibitors in the Treat and 5.0. ment and Prevention of Breast Cancer. J. Clin. Oncol. 19, 60 5. The nanochannel delivery device of claim 3 wherein the 881-894 (2001). ratio of the nanochannel length to either the inlet microchan 3 Chlebowski, R.T. Reducing the Risk of Breast Cancer. N. nel length or the outlet microchannel length is between 0.3 Engl. J. Med., 343, 191-198 (2000). and 3.0. 4 Dowsett, M., Jones, A., Johnston, S.R., Jacobs, S., Trunet, 6. The nanochannel delivery device of claim 3 wherein the P., Smith, I. E. In vivo measurement of aromatase inhibi 65 ratio of the nanochannel length to either the inlet microchan tion by letrozole (CGS 20267) in postmenopausal patients nel length or the outlet microchannel length is between 0.4 with breast cancer. Clin. Cancer Res. 1, 1511-1515 (1995). and 2.0. US 8,480,637 B2 49 50 7. The nanochannel delivery device of claim 3 wherein the an inlet microchannel in fluid communication with the ratio of the nanochannel length to either the inlet microchan nanochannel; and nel length or the outlet microchannel length is between 0.5 an outlet microchannel in fluid communication with the and 1.0. nanochannel, wherein the inlet microchannel and 8. The nanochannel delivery device of claim 3 wherein the nanochannel are configured Such that a first linear axis inlet microchannel is in direct fluid communication with the can extend between the inlet surface and the inlet end of outlet microchannel via a single nanochannel. the nanochannel. 9. A nanochannel delivery device comprising: 13. An apparatus comprising the nanochannel delivery a planar body comprising a first Surface and a second device of claim 1 inserted into a capsule. Surface opposing the first Surface; 10 an inlet microchannel; 14. A nanochannel delivery device comprising: nanochannel disposed within the planar body between the a planar body comprising a first Surface and a second first surface and the second surface, wherein the Surface opposing the first Surface; nanochannel is oriented parallel to the primary plane of a plurality of inlet microchannels, wherein each of the inlet the nanochannel delivery device; 15 microchannels has a length, a width, and a depth, and an outlet microchannel, wherein the inlet microchannel wherein the inlet microchannel length is greater than the extends from the nanochannel to the first surface and inlet microchannel width and depth: wherein the outlet microchannel extends from the a plurality of outlet microchannels, wherein each of the nanochannel to the second Surface; and outlet microchannels has a length, a width, and a depth; a fluid flow path from the inlet microchannel to the outlet a plurality of nanochannels disposed within the planar microchannel, wherein the fluid flow path requires a body between the first surface and the second surface maximum of two changes in direction. and in fluid communication with the plurality of inlet 10. A nanochannel delivery device comprising: microchannels and outlet microchannels, wherein: a planar body comprising a first Surface and a second the plurality of inlet microchannels extend to the first Surface opposing the first Surface; 25 surface and wherein the plurality of outlet microchan a nanochannel disposed within the planar body between nels extend to the second Surface; the first surface and the second surface; the plurality of inlet microchannels are arranged so that an inlet microchannel in fluid communication with the the inlet microchannel width and depth define a first nanochannel; and plane that is parallel to the primary plane of the an outlet microchannel in fluid communication with the 30 nanochannel delivery device; and nanochannel, wherein the inlet microchannel extends from the nanochannel to the first surface and wherein the the plurality of outlet microchannels are arranged so that outlet microchannel extends from the nanochannel to the outlet microchannel width and depth define a sec the second Surface. ond plane that is parallel to the primary plane of the 11. A nanochannel delivery device comprising: 35 nanochannel delivery device. a planar body comprising a first Surface and a second 15. A method of treating a condition of a person, the Surface opposing the first Surface; method comprising: a plurality of inlet microchannels; providing a nanochannel delivery device, wherein the a plurality of nano channels disposed within the planar nanochannel delivery device comprises: body between the first surface and the second surface; 40 a planar body comprising a first Surface and a second and Surface opposing the first Surface; a plurality of outlet microchannels, wherein each inlet an inlet microchannel; microchannel is in direct fluid communication with an a nanochannel disposed within the planar body between outlet microchannel via a single nanochannel, wherein the first surface and the second surface; the plurality of inlet microchannels extend to the first 45 an outlet microchannel, wherein the inlet microchannel surface and wherein the plurality of outlet microchan and the outlet microchannel are in fluid communica nels extend to the second Surface. tion with the nanochannel; 12. A nanochannel delivery device comprising: the inlet microchannel extends from the nanochannel to a planar body including: the first surface; a length, a width, and a thickness, wherein the length and 50 the outlet microchannel extends from the nanochannel the width are each greater than the thickness; an inlet surface on a first side of the planar body, wherein to second Surface; and the inlet surface is bounded by the length and the width the nanochannel is oriented parallel to the primary plane of the planar body; and of the nanochannel delivery device; an outlet Surface on a second side of the planar body, 55 providing a reservoir in fluid communication with the wherein the outlet surface is bounded by the length and nanochannel delivery device; the width of the planar body, and wherein the inlet sur providing a substance in the reservoir, wherein the Sub face is substantially parallel with the outlet surface; stance is configured to treat the condition; and a nanochannel disposed within the planar body between administering the Substance to the person via the the first surface and the second surface, wherein the 60 nanochannel delivery device. nanochannel comprises an inlet end and an outlet end; k k k k k UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. : 8,480,637 B2 Page 1 of 1 APPLICATIONNO. : 12/618233 DATED : July 9, 2013 INVENTOR(S) : Mauro Ferrari et al. It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

In claim 1, column 48, line 40, delete “Second the and insert --the Second-- therefor.

In claim 9, column 49, line 12, before “nanochannel, insert --a--.

In claim 11, column 49, line 39, delete “nano channels and insert--nanochannels-- therefor.

Signed and Sealed this Twenty-ninth Day of October, 2013 2 2-Y xx 26-e-s? 2.é--.SX -13 . . Teresa Stanek Rea Deputy Director of the United States Patent and Trademark Office